Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 2709. Отображено 100.
14-06-2012 дата публикации

Enzyme inhibitors

Номер: US20120149736A1
Принадлежит: Chroma Therapeutics Ltd

Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-nat-ural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(═O)—, —S(═O)2—, —C(═O)O—, —C(═O)NR′—, —C(═5)—NR′, —C(═NH)NR′ or —S(═O) 2 NR — wherein R′ is hydrogen or optionally substituted C 1 —C 6 alkyl; L 1 is a divalent radical of formula —(Alk 1 ) m ,(Q) n (Alk 2 ) p — wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —,— NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R4 and R5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

Подробнее
20-12-2012 дата публикации

Method of producing beraprost

Номер: US20120323025A1
Принадлежит: Lung LLC

An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Подробнее
08-08-2013 дата публикации

Pharmaceutical Formulation for Histone Deacetylase Inhibitors

Номер: US20130203847A1
Принадлежит: SHAPE PHARMACEUTICALS, INC.

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein. 2. The pharmaceutical composition of claim 1 , wherein the at least one acidifying agent is selected from the groups consisting of acetic acid claim 1 , dehydro acetic acid claim 1 , ascorbic acid claim 1 , benzoic acid claim 1 , boric acid claim 1 , citric acid claim 1 , edetic acid claim 1 , hydrochloric acid claim 1 , isostearic acid claim 1 , stearic acid claim 1 , lactic acid claim 1 , nitric acid claim 1 , oleic acid claim 1 , phosphoric acid claim 1 , sorbic acid claim 1 , sulfuric acid claim 1 , tartaric acid claim 1 , and undecylenic acid.3. The pharmaceutical composition of claim 2 , wherein the at least one acidifying agent is selected from citric acid claim 2 , acetic acid claim 2 , and phosphoric acid.4. The pharmaceutical composition of claim 1 , wherein the at least one pharmaceutically acceptable non-aqueous solvent is selected from the groups consisting of ethanol claim 1 , acetone claim 1 , benzyl alcohol claim 1 , 2-(2-ethoxyethoxy)ethanol claim 1 , diethylene glycol monoethyl ether claim 1 , glycerin claim 1 , propylene glycol claim 1 , propylene carbonate claim 1 , acetone claim 1 , hexylene glycol claim 1 , isopropyl alcohol claim 1 , polyethylene glycols (PEGs) claim 1 , methoxypolyethylene glycols claim 1 , diethyl sebacate claim 1 , dimethyl isosorbide claim 1 , propylene carbonate claim 1 , dimethyl sulfoxide (DMSO) claim 1 , diisopropyl adipate claim 1 , isopropyl myristate claim 1 , vegetable oils claim 1 , a mineral oil claim 1 , and isopropyl palmitate.5. The pharmaceutical composition of claim 4 , wherein the at least one pharmaceutically acceptable ...

Подробнее
05-09-2013 дата публикации

Ethynylbenzene derivatives

Номер: US20130231323A1
Автор: Eric J. Toone, Pei Zhou
Принадлежит: Duke University

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R 1 , R 2 , R 3 , R 101 , L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Подробнее
19-09-2013 дата публикации

Synthetic Ion Channels

Номер: US20130244944A1
Автор: Li Xiang, Yang Dan, Zha Huiyan
Принадлежит:

Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating or preventing conditions and diseases that are related to the dysfunction of ion channels, including chloride channels. 2. The self-assembling compound of claim 1 , wherein Y is a monovalent claim 1 , divalent claim 1 , trivalent claim 1 , tetravalent claim 1 , pentavalent or hexavalent linking group formed by removing one claim 1 , two claim 1 , three claim 1 , four claim 1 , five and six hydrogen atoms respectively from an unsubstituted or substituted hydrocarbon or carbocycle.3. The self-assembling compound of claim 1 , wherein at least one of Zor Zis S or NR'.4. The self-assembling compound of claim 1 , wherein at least one of A claim 1 , B claim 1 , and D is O or S.5. The self-assembling compound of claim 1 , wherein each of A and D is a bond.6. The self-assembling compound of claim 1 , wherein each of B claim 1 , B claim 1 , and Bis independently NH.7. The self-assembling compound of claim 1 , wherein X is hydrocarbyl or substituted hydrocarbyl.10. The self-assembling compound of claim 9 , wherein at least one of Zor Zis S or NR.11. The self-assembling compound of claim 9 , wherein at least one of A claim 9 , B claim 9 , C claim 9 , and D is O or S.12. The self-assembling compound of claim 9 , wherein each of B claim 9 , B claim 9 , and Bis independently NH.13. A composition claim 9 , comprising a cell membrane and a plurality of molecules of the self-assembling compound of .14. The composition of claim 13 , wherein the cell membrane comprises a lipid bilayer.15. The composition of claim 14 , wherein the plurality of molecules self-assemble to form an anion channel across the thickness of the lipid ...

Подробнее
03-10-2013 дата публикации

Compounds and methods for delivery of prostacyclin analogs

Номер: US20130261187A1
Автор: David Mottola, Ken Phares
Принадлежит: United Therapeutics Corp

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

Подробнее
24-10-2013 дата публикации

Compounds for the treatment of metabolic disorders

Номер: US20130281705A1
Автор: Shalini Sharma
Принадлежит: Wellstat Therapeutics Corp

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Подробнее
14-11-2013 дата публикации

Enzyme inhibitors

Номер: US20130303576A1
Принадлежит: Chroma Therapeutics Ltd

Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH—Or —CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither R 2 nor R 3 is hydrogen, or R 2 and R 3 , taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(═O)—, —S(═O) 2 —, —C(═O)O—, —C(═O)NR′—, —C(═S)—NR′, —C(═NH)NR′ or —S(═O) 2 NR— wherein R′ is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q. Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

Подробнее
12-12-2013 дата публикации

DEACETYLASE INHIBITORS AND USES THEREOF

Номер: US20130331455A1
Принадлежит:

The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds. 1. (canceled)2. The method of claim 27 , wherein n is 4 to 7 claim 27 , inclusive.34-. (canceled)5. The method of claim 2 , wherein n is 6.6. The method of claim 27 , wherein m is 0 claim 27 , 1 claim 27 , or 2.7. The method of claim 27 , wherein p is 0 claim 27 , 1 claim 27 , or 2.8. The method of claim 27 , wherein k is 0 claim 27 , 1 claim 27 , or 2.911-. (canceled)12. The method of claim 27 , wherein Ris —C(═O)R claim 27 , wherein Ris selected from —OR′ or —N(R″) claim 27 , wherein R′ is hydrogen or an optionally substituted alkyl moiety claim 27 , and wherein R″ is hydrogen claim 27 , —OH claim 27 , an optionally substituted aryl moiety claim 27 , or an optionally substituted heteroaryl moiety.13. The method of claim 12 , wherein Ris —COH.14. The method of claim 12 , wherein Ris —OR′; and R′ is an optionally substituted alkyl.15. (canceled)16. The method of claim 12 , wherein Ris selected from —NHR″ claim 12 , and wherein R″ is selected from —OH claim 12 , optionally substituted aryl claim 12 , or optionally substituted heteroaryl.17. The method of claim 16 , wherein R″ is —OH.18. The method of claim 16 , wherein R″ is an optionally substituted aryl moiety.2226-. (canceled)28. The method according to claim 27 , wherein the subject is a mammal.29. The method according to claim 28 , wherein the subject is human.30. The method according to claim 27 , wherein the proliferative disorder is cancer.31. The method according to claim 27 , wherein the proliferative disorder is an inflammatory disease.32. The method according to claim 27 , wherein the ...

Подробнее
19-12-2013 дата публикации

SURFACE-MODIFIED ZIRCONIA NANOPARTICLES

Номер: US20130338251A1
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

Surface-modified zirconia nanoparticles include zirconia nanoparticles and surface-modifying ligands attached to the zirconia nanoparticles. The ligand includes a hydroxamate functionality, and either a reactive group or an oligomeric group. Reactive groups include chain transfer groups or photoinitiator groups. Oligomeric groups include poly(meth)acrylate or poly(meth)acrylamide groups. Articles can be prepared that include the surface-modified zirconia nanoparticles in an organic matrix. 1. Surface-modified nanoparticles comprising:zirconia nanoparticles; and a hydroxamate functionality; and', 'a reactive group comprising a chain transfer group or a photoinitiator group., 'at least one ligand attached to at least one of the zirconia nanoparticles, the ligand comprising2. The surface-modified nanoparticles of claim 1 , wherein the chain transfer group comprises a thiol group.3. The surface-modified nanoparticles of claim 1 , wherein the ligand comprises the structure:{'br': None, 'sup': '1', 'RN(OH)(CO)-A-X'}{'sup': '1', 'wherein Ris selected from a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, an aralkyl group, a heteroaryl group, or a heterocycloalkyl group;'}(CO) is a carbonyl group C═O;A is a divalent linking group selected from alkylene, arylene, aralkylene, heteroalkylene, heteroarylene, or heteroaralkylene; and{'sup': '2', 'sub': '2', 'X is —SH or —(OC)—O—B—O—Ar—(CO)—C(OH)R'}wherein B is an alkylene group or arylene group;Ar is an aryl or substituted aryl group; and{'sup': '2', 'each Ris an alkyl group.'}4. The surface-modified nanoparticles of claim 1 , further comprising at least one additional ligand comprising a hydroxamate functionality.5. The surface-modified nanoparticles of claim 4 , wherein the at least one additional ligand comprises the structure:{'br': None, 'sup': 1', '3, 'RN(OH)(CO)—R'}{'sup': '1', 'wherein Ris selected from a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl ...

Подробнее
30-01-2014 дата публикации

SELECTIVE HDAC INHIBITORS

Номер: US20140031368A1
Принадлежит:

This disclosure is related to compounds having the structure 5. (canceled)8. The compound of claim 6 ,wherein{'sub': 1', '7', '8', '7', '7', '8', '1-5', '51', '52, 'claim-text': {'sub': 7', '8', '51', '1', '5', '52, 'wherein Rand Rare each, independently, H or heteroaryl and wherein Ris H or a C-Calkyl and Ris heteroaryl;'}, 'Ris H, halogen, —NRR, —OR, —(C═O)—NRR, Calkyl or NR—C(═O)—NR,'}or a pharmaceutically acceptable salt thereof.10. (canceled)12. (canceled)14. (canceled)15. The compound of claim 11 , wherein m is an integer from 0 to 2 and n is an integer from 3 to 8;or a pharmaceutically acceptable salt thereof.16. (canceled)17. The compound of claim 15 ,wherein{'sub': 6', '49', '49, 'claim-text': {'sub': 49', '1-10, 'wherein Ris H or Calkyl;'}, 'Ris —ORor —NH—OR,'}or a pharmaceutically acceptable salt thereof.2023-. (canceled)26. (canceled)28. (canceled)3031-. (canceled)32. A pharmaceutical composition comprising the compound of any one of and a pharmaceutically acceptable carrier.33. A method of inhibiting the activity of a histone deacetylase in a cell comprising contacting the histone deacetylase with the compound of so as to inhibit the activity of the histone deacetylase claim 1 , preferably HDAC6.3440-. (canceled) This application claims priority of U.S. Provisional Applications Nos. 61/347,337, filed May 21, 2010; 61/402,945, filed Sep. 7, 2010; and 61/442,681, filed Feb. 14, 2011, the contents of which are hereby incorporated by reference.Throughout this application, certain publications are referenced in parentheses. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention relates.To date, eighteen histone deacetylases (HDACs) have been identified in humans. Eleven HDACs (HDAC1-11) are zinc-dependent and seven HDACs, designated ...

Подробнее
13-02-2014 дата публикации

Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof

Номер: US20140045943A1
Принадлежит: NAUREX, INC.

Disclosed are amino alkyl/aryl hydroxamic acid compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for degenerative diseases in mammal. 2. The compound of claim 1 , wherein Ris hydrogen.3. The compound of claim 1 , wherein Ris H.4. The compound of claim 1 , wherein Ris a lower alkyl group.5. The compound of claim 1 , wherein X is oxygen.6. The compound of claim 1 , wherein Ris NH.7. The compound of claim 1 , wherein Ris CH—C(O)—NH—.8. The compound of claim 1 , wherein Ris iso-butyl.9. The compound of claim 1 , wherein Ris propyl.10. The compound of claim 1 , wherein Rand Rare connected to a chiral center.11. The compound of claim 1 , wherein the compound is selected from the group consisting of: 2-amino-N-hydroxy-4-methylpentamide (Salt TFA) claim 1 , 2-acetoamido-N-hydroxy-4-methylpentamide claim 1 , 2-amino-N-hydroxypentamide (Salt TFA) claim 1 , 3-amino-N-hydroxy-4-methylpentamide (Salt TFA) claim 1 , 2-amino-N-hydroxypropanamide (Salt TFA) claim 1 , 2-amino-N-hydroxybutanamide (Salt TFA) claim 1 , 2-amino-N-hydroxy-3-methylpentamide (Salt TFA) claim 1 , and 2-amino-N-hydroxy-4-methylpentamide (Salt TFA).12. A method of treating or preventing a degenerative disease in a mammal comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising the compound of .13. A method of decreasing cell death in a mammal comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising the compound of . This application is a continuation of U.S. application Ser. No. 13/118,879, filed May 31, 2011, which is a continuation of PCT/US2009/066536 filed Dec. 3, 2009, which claims priority to U.S. Ser. No. 61/119,514, filed Dec. 3, 2008, which is hereby incorporated by reference in its entirety.The translation of degenerative disease mechanisms into effective therapeutics has been meager and disappointing. While ...

Подробнее
06-03-2014 дата публикации

HYDROXAMIC ACID DERIVATIVES

Номер: US20140066419A1
Автор: CHEN Yi, Chen Yu
Принадлежит: PURDUE PHARMACEUTICAL PRODUCTS L.P.

The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: 2. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Z is deleted , CH , O , CO , NH , SO , OC(O) , C(O)O , C(O)S , NHC(O) , C(O)NH , OC(O)NH , NHC(O)O , or NHC(O)S; m is 5 , 6 , 7 , or 8.3. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Q is an aryl or heteroaryl.4. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Q is a 9-10 membered aryl or heteroaryl.8. A method of alleviating claim 1 , relieving claim 1 , altering claim 1 , remedying claim 1 , ameliorating claim 1 , improving or affecting a neoplastic disease according to claim 1 , wherein said neoplastic disease is selected from the group consisting of lung cancer claim 1 , head and neck cancer claim 1 , central nervous system cancer claim 1 , prostate cancer claim 1 , testicular cancer claim 1 , colorectal cancer claim 1 , pancreatic cancer claim 1 , liver cancer claim 1 , stomach cancer claim 1 , biliary tract cancer claim 1 , esophageal cancer claim 1 , gastrointestinal stromal tumor claim 1 , breast cancer ...

Подробнее
20-03-2014 дата публикации

Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents

Номер: US20140081017A1
Принадлежит: METHYLGENE INC.

The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds. The compositions of the invention are comprised of a combination of a histone deacetylase inhibitor, or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, agricultural formulation, prodrug or complex thereof, and an antifungal agent, the histone deacetylase inhibitor being a compound of Formula (I): 119.-. (canceled)21. The inhibitor of claim 20 , where B is phenyl.24. The inhibitor of claim 20 , where the butyl group is substituted at one or more positions with one or two methyl claim 20 , ethyl claim 20 , fluoro claim 20 , chloro claim 20 , bromo claim 20 , or hydroxyl groups claim 20 , or one oxo claim 20 , amino claim 20 , or oxime group.25. The inhibitor of claim 24 , where the butyl group is substituted at one position with one methyl claim 24 , ethyl claim 24 , fluoro claim 24 , chloro claim 24 , bromo claim 24 , oxo claim 24 , amino claim 24 , oxime or hydroxyl group.26. The inhibitor of claim 24 , where the butyl group is substituted at the same position with two methyl claim 24 , ethyl claim 24 , fluoro claim 24 , chloro claim 24 , bromo or hydroxyl groups.27. The inhibitor of claim 20 , where the butyl group is unsubstituted.28. The inhibitor of claim 20 , where Rand Rare independently hydrogen or methyl.29. (canceled)30. (canceled)32. (canceled)34. A histone deacetylase inhibitor selected from the group consisting of:N-hydroxy-2-(2-(4-phenylbutyl)thiazol-4-yl)acetamide,N-hydroxy-2-(2-(4-phenylbutyl)thiazol-5-yl)acetamide,2-(4-(4-(2,4-difluorophenyl)butyl)phenyl)-N-hydroxyacetamide,N-hydroxy-2-(4-(4-p-tolylbutyl)phenyl)acetamide,2-(4-(4-(biphenyl-4-yl)butyl)phenyl)-N-hydroxyacetamide,N-hydroxy-2-(4-(4-(1-methyl-1H-indol-5-yl)butyl)phenyl)acetamide,2,2′-(4,4′-(butane-1,4-diyl)bis(4,1- ...

Подробнее
20-01-2022 дата публикации

Surface treatment agent, surface treatment method, and region selective film formation method for surface of substrate

Номер: US20220017455A1
Принадлежит: Tokyo Ohka Kogyo Co Ltd

A surface treatment agent used for treating a substrate which has a surface having two or more regions made of materials that are different from each other, the agent including a compound (H) represented by Formula (H-1). In the formula, R1 represents a linear or branched alkyl group having 1 to 30 carbon atoms, a linear or branched fluorinated alkyl group having 1 to 30 carbon atoms, an aromatic hydrocarbon group, or a cycloalkyl group having 3 to 12 carbon atoms, and R2 represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, or a cycloalkyl group having 3 to 12 carbon atoms)

Подробнее
09-01-2020 дата публикации

NOVEL IMAGING COMPOSITION AND USES THEREOF

Номер: US20200009090A1
Принадлежит:

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours. 2. The conjugate of claim 1 , wherein L is OR.3. The conjugate of claim 2 , wherein R is Cto Calkyl.4. The conjugate of claim 2 , wherein OR is selected from O-p-toluenesulfonate claim 2 , O-methanesulfonate claim 2 , O-trifluoromethanesulfonate claim 2 , O-benzenesulfonate claim 2 , and O-m-nitrobenzenesulfonate.5. The conjugate of claim 1 , wherein the target molecule is a polypeptide.6. The conjugate of claim 5 , wherein the polypeptide is an antibody.7. The conjugate of claim 6 , wherein the antibody is selected from trastuzumab claim 6 , rituximab and cetuximab.8. The conjugate of claim 1 , wherein the target molecule is a peptide.9. The conjugate of claim 8 , wherein the peptide is a targeting peptide.10. The conjugate of claim 9 , wherein the targeting peptide is selected from a cyclic RGD sequence claim 9 , bombesin and glu-N(CO)N-lys PSMA. This application is a Continuation of U.S. patent application Ser. No. 15/963,599, filed Apr. 26, 2018, which is a Continuation of U.S. patent application Ser. No. 15/518,333, filed Apr. 11, 2017, now U.S. Pat. No. 9,980,930, issued on May 29, 2018 and is a National Stage Application, filed under 35 U.S.C. 371, of International Application No. PCT/AU2015/050640, filed on Oct. 16, 2015, which claims priority to, and the benefit of, AU Application No. 2014904138, filed Oct. 16, 2014. The contents of each of these applications are incorporated by reference in their entirety.The present invention relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours. The present invention also relates to compositions including the compounds, and to methods of imaging patients using the compounds.Zirconium-89 (Zr) is a positron-emitting ...

Подробнее
09-01-2020 дата публикации

Retinoid derivatives with antitumor activity

Номер: US20200009091A1
Принадлежит: Biogem Sc A Rl

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.

Подробнее
14-01-2021 дата публикации

INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS)

Номер: US20210009511A1
Принадлежит:

A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases. 16-. (canceled)89-. (canceled)11. (canceled)13. A pharmaceutical composition comprising a compound of Formula (IIb).14. The pharmaceutical composition of claim 13 , further comprising one or more additional therapeutic agents.15. The pharmaceutical composition of claim 14 , wherein the one or more additional therapeutic agents is selected from the group consisting of a histone deacetylase (HDAC) inhibitor claim 14 , a DNA methyltransferase (DNMT) inhibitor claim 14 , and combinations thereof.16. A method for inhibiting lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) claim 14 , the method comprising administering to a subject a compound of Formula (IIb) claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , in an amount effective to inhibit LSD1 or one or more HDACs.18. The method of claim 17 , wherein the disease claim 17 , disorder claim 17 , or condition associated with LSD1 and/or one or more histone deacetylases (HDACs) is a cancer.19. The method of claim 17 , wherein the treating of the disease claim 17 , disorder claim 17 , or condition associated with LSD1 and/or one or more histone deacetylases (HDACs) includes activating one or more tumor suppressors silenced in cancer by an epigenetic ...

Подробнее
03-02-2022 дата публикации

HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF

Номер: US20220033369A1
Принадлежит:

The present disclosure is related to the field of enzyme inhibitors, and in particular to a hydroxamic acid derivative, a method for producing the same and use thereof. The hydroxamic acid group of the hydroxamic acid derivative can be chelated with zinc ions in the LpxC active area, and the derivative has a hydrophobic side chain which can bind to hydrophic channels in the enzyme LpxC. These guarantee that the hydroxamic acid derivative has good bactericidal activity against Gram-negative bacteria and low toxicity. The present disclosure also provides a method for producing the hydroxamic acid derivative, which requires a shorter reaction time and can provide the derivative with a high yield. 115.-. (canceled)20. The method according to claim 18 , wherein claim 18 , the molar ratio of the Dess-Martin periodinane to the compound of Formula (II) is 1.0 to 1.2.21. The method according to claim 19 , wherein claim 19 , the molar ratio of the Dess-Martin periodinane to the compound of Formula (II) is 1.0 to 1.2.22. The method according to claim 18 , wherein claim 18 , the oxidation reaction is conducted at room temperature for 2 to 8 hours.23. The method according to claim 20 , wherein claim 20 , the oxidation reaction is conducted at room temperature for 2 to 8 hours.24. The method according to claim 18 , wherein claim 18 , the molar ratio of the compound of Formula (III)/triphenylphosphine/carbon tetrabromide is 1:(3.8-4.2):(1.8-2.2).25. The method according to claim 18 , wherein claim 18 , the Corey-Fuchs reaction is conducted at a temperature of −20 to −78° C.26. The method according to claim 24 , wherein claim 24 , the Corey-Fuchs reaction is conducted at a temperature of −20 to −78° C.27. The method according to claim 18 , wherein claim 18 , the molar ratio of the compound of Formula (IV)/tris(dibenzylideneacetone)dipalladium/the compound of Formula (a)/triethylamine is 1:(0.02-0.04):(1.8-2.2):(2.8-3.2).28. The method according to claim 18 , wherein claim 18 , the ...

Подробнее
21-01-2016 дата публикации

ANTIBACTERIAL AGENTS

Номер: US20160016895A1
Принадлежит:

Antibacterial compounds of formula (I) are provided: 2. A compound according to claim 1 , wherein A is substituted C-Calkyl claim 1 , wherein at least one substituent is hydroxy.3. A compound according to claim 2 , wherein A is substituted C-Calkyl claim 2 , wherein at least two substituents are hydroxy.4. A compound according to claim 2 , wherein A is hydroxymethyl claim 2 , hydroxyethyl claim 2 , hydroxypropyl or dihydroxpropyl.5. A compound according to claim 1 , wherein A is substituted C-Ccycloalkyl claim 1 , wherein at least one substituent is selected from hydroxy and hydroxyalkyl.6. A compound according to claim 5 , wherein A is substituted C-Ccycloalkyl claim 5 , wherein at least one substituent is hydroxymethyl.7. A compound according to claim 6 , wherein A is hydroxymethylcyclopropyl.8. A compound according to claim 5 , wherein A is substituted C-Ccycloalkyl claim 5 , wherein at least one substituent is hydroxy.9. A compound according to claim 1 , wherein G is —C≡C—C≡C—.1012-. (canceled)14. A compound according to claim 13 , wherein Ris hydrogen.15. A compound according to claim 13 , wherein Ris hydrogen.16. A compound according to claim 13 , wherein E is —C(CH)SCH.17. A compound according to claim 13 , wherein E is —C(CH)S(O)CH.18. A compound according to claim 13 , wherein E is —C(CH)S(O)CH.19. (canceled)20. A compound selected from the group consisting of:N-hydroxy-2-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 1);N—((R)-1-(hydroxyamino)-3-methyl-3-(methylthio)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (Compound 2);N-((2R)-1-(hydroxyamino)-3-methyl-3-(methylsulfinyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (Compound 3);N-((2R)-1-(hydroxyamino)-3-methyl-3-(methylsulfinyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (Compound 4);N—((R)-1-(hydroxyamino)-3-methyl-3-( ...

Подробнее
15-01-2015 дата публикации

ANTIBACTERIAL AGENTS

Номер: US20150018331A1
Принадлежит: Achaogen, Inc.

Antibacterial compounds of formula (I) are provided: 137-. (canceled)39. A compound of wherein A is —C(R claim 38 ,R)N(R claim 38 ,R).40. A compound of wherein A is —C(CH)NH.41. A compound of wherein A is —C(R claim 38 ,R)OR.42. A compound of wherein A is selected from the group consisting of:{'sub': 3', '10, '(1) substituted or unsubstituted C-C-cycloalkyl,'}(2) substituted or unsubstituted heterocyclyl, and(3) substituted or unsubstituted heteroaryl.44. (canceled)45. A compound of wherein G is selected from the group consisting of:(1) —C≡C—,(2) —C≡C—C≡C—,{'sup': 3G', '3G, '(3) —CR═CR—C≡C—, and'}{'sup': 3G', '3G, '(4) —C≡C—CR═CR—.'}46. A compound of wherein G is selected from the group consisting of:(1) —C≡C—,(2) —C≡C—C≡C—,(3) —CH═CH—C≡C—, and(4) —C≡C—CH═CH—.47. A compound of wherein G is —C≡C—.48. A compound of wherein G is —C≡C—C≡C—.49. A compound of wherein G is —CH═CH—C≡C—.50. (canceled)51. A compound of wherein G is —C≡C—CH═CH—.5257-. (canceled)58. A compound of wherein Ris H.59. A compound of wherein Y is substituted or unsubstituted aryl.60. A compound of wherein Y is substituted or unsubstituted phenyl.61. A compound of wherein Y is unsubstituted phenyl.62. (canceled)63. A compound of wherein D is substituted or unsubstituted heteroaryl.6467-. (canceled)68. A compound of wherein D is absent.6972-. (canceled)73. A compound of wherein L is absent.74. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier or diluent.75. A method for treating a subject with a gram-negative bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of or a pharmaceutical composition of .76. (canceled) This application is a continuation of U.S. patent application Ser. No. 12/635,551, filed Dec. 10, 2009, now pending, which is a continuation of International PCT Application No. PCT/US2008/066766, filed Jun. 12, 2008, which claims the benefit under 35 U.S.C. §119(e) of U.S. ...

Подробнее
15-01-2015 дата публикации

PROCESS FOR THE PREPARATION OF VORINOSTAT

Номер: US20150018424A1
Принадлежит:

The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient vorinostat. In particular it relates to a process for preparing vorinostat substantially free from impurities. 1. A process for the preparation of vorinostat comprising:(a′) reacting suberic acid with hydroxylamine, or a salt thereof, to form N-hydroxy-7-carboxy-heptanamide; and(b′) reacting the N-hydroxy-7-carboxy-heptanamide formed in step (a′) with aniline, or a salt thereof.2. The process according to claim 1 , wherein:step (a′) involves a coupling agent; and/or(ii) step (a′) involves a coupling agent selected from 1,3-dicyclohexylcarbodiimide (DCC); 1,1′-carbonyldiimidazole (CDI); 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (WSC.HCl); 1,3-diisopropylcarbodiimide (DIC); or a mixture thereof; and/or(iii) step (a′) involves a coupling agent, wherein the coupling agent is 1,1′-carbonyldiimidazole (CDI); and/or(iv) step (a′) involves a coupling agent, and wherein the total amount of coupling agent used in step (a′) with respect to the suberic acid is between 1 to 5 molar equivalents; and/or(v) step (a′) is carried out in an organic solvent; and/or(vi) step (a′) is carried out in an organic solvent selected from dimethylformamide (DMF), tetrahydrofuran (THF), dichloromethane (DCM), acetonitrile, 1,2-dichlorobenzene, ethanol, or a mixture thereof; and/or(vii) step (a′) is carried out in DMF; and/or(viii) in step (a′) hydroxylamine is used in the form of a salt; and/or(ix) in step (a′) hydroxylamine is used in the form of the hydrochloride salt; and/or(x) the total amount of hydroxylamine, or its salt, used in step (a′) with respect to the suberic acid is about 1 molar equivalent; and/or(xi) step (a′) is carried out at a temperature of between 10-60° C.3. The process according to claim 1 , wherein:(i) step (b′) involves a coupling agent; and/orstep (b′) involves a coupling agent selected from 1,3-dicyclohexylcarbodiimide (DCC); 1,1′- ...

Подробнее
15-01-2015 дата публикации

TUBULIN BINDING AGENTS

Номер: US20150018566A1
Принадлежит:

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature. 143-. (canceled)45. A compound of in which at least one of X claim 44 , Y and Z is C═O.46. A compound of in which Rand Rare each independently selected from H and a halogen.47. A compound of in which Rand Rare each claim 44 , independently claim 44 , selected from H claim 44 , OH claim 44 , amino and L(W).48. A compound according to in which Rand Rare each claim 44 , independently claim 44 , selected from H claim 44 , NH claim 44 , lower alkoxy claim 44 , alkylthio and OH.49. A compound according to in which Ris a lower alkoxy group in the para position.50. A compound according to in which Rand Rare each independently selected from H and a halogen claim 44 , Rand Rare each claim 44 , independently claim 44 , selected from OH claim 44 , amino and L(W) claim 44 , and Rand Rare each claim 44 , independently claim 44 , ...

Подробнее
17-01-2019 дата публикации

TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION

Номер: US20190016670A1

The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: 19-. (canceled)11. The process of claim 10 , wherein the second suitable solvent is chloroform claim 10 , dichloromethane claim 10 , nitromethane claim 10 , dimethylforamide claim 10 , diethyl ether claim 10 , tetrahydrofuran claim 10 , dioxane claim 10 , dichloroethane claim 10 , or hexane.12. The process of claim 10 , wherein step (b) is carried out at room temperature.13. The process of claim 10 , wherein step (b) is carried out at a temperature of 50-140° C.14. The process of claim 10 , wherein the compound is maintained in the second suitable solvent for 10-50 hours.15. The process of claim 10 , wherein A is a phenyl or pyridine.16. The process of claim 10 , wherein A is a furan claim 10 , thiophene claim 10 , pyrrole claim 10 , thiazole claim 10 , imidazole claim 10 , pyrazole claim 10 , isooxazole claim 10 , isothiazole claim 10 , naphthalene claim 10 , anthracene claim 10 , pyrimidine claim 10 , pyrazine claim 10 , pyridazine claim 10 , indole claim 10 , indoline claim 10 , benzofuran claim 10 , benzothiophene claim 10 , or quinolone.2037-. (canceled) This application claims priority of U.S. Provisional Application Nos. 62/192,789, filed Jul. 15, 2015; 62/192,462, filed Jul. 14, 2015; 62/063,246, filed Oct. 13, 2014; and 62/062,508, filed Oct. 10, 2014, the contents of each of which are hereby incorporated by reference.Throughout this application various publications are referenced. The disclosures of these documents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.Fluorine atoms are often introduced into organic molecules to enhance their pharmacological properties such as solubility, metabolic and oxidative stability, lipophilicity, and bioavailability. Among the fluorine containing functional groups, ...

Подробнее
17-01-2019 дата публикации

SYSTEM FOR PRODUCING REMOTE SENSING DATA FROM NEAR EARTH ORBIT

Номер: US20190016672A1
Принадлежит:

A satellite system operates at altitudes between 180 km and 350 km relying on vehicles including an engine to counteract atmospheric drag to maintain near-constant orbit dynamics. The system operates at altitudes that are substantially lower than traditional satellites, reducing size, weight and cost of the vehicles and their constituent subsystems such as optical imagers, radars, and radio links. The system can include a large number of lower cost, mass, and altitude vehicles, enabling revisit times substantially shorter than previous satellite systems. The vehicles spend their orbit at low altitude, high atmospheric density conditions that have heretofore been virtually impossible to consider for stable orbits. Short revisit times at low altitudes enable near-real time imaging at high resolution and low cost. At such altitudes, the system has no impact on space junk issues of traditional LEO orbits, and is self-cleaning in that space junk or disabled craft will de-orbit. 1. A satellite configured to maintain an orbit between 180 km and 350 km , the satellite being one of a plurality of satellites in a satellite system , the satellite comprising:a vehicle bus comprising:a frontal section having at least one beveled surface configured to reduce drag; anda material applied to at least a portion of the at least one beveled surface to provide at least partial specular reflection of incident atmospheric particles, the at least one beveled surface and the material configured to reduce drag on and damage to the material from interactions with atmospheric particles incident to at least one of the satellites of the plurality of satellites during orbit by the partial specular reflection of the atmospheric particles.2. The satellite defined in claim 1 , wherein the at least one beveled surface and the material are configured to reduce drag on the frontal section by more than 25 percent compared to the same frontal section geometry with a material that results in fully diffuse ...

Подробнее
28-01-2016 дата публикации

Photoswitchable HDAC Inhibitors

Номер: US20160022817A1
Принадлежит: The General Hospital Corporation

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds are diazo compounds including a substituted or unsubstituted aryl or heteroaryl ring, wherein at least one of the rings is substituted with one or more HDAC targeting elements. 2. The compound of claim 1 , wherein Y is substituted by one or more HDAC targeting elements and X is substituted by one or more fluorescent moieties.4. The compound of claim 1 , wherein Ris an electron withdrawing group.5. The compound of claim 4 , wherein each Ris independently selected from the group consisting of: NRR claim 4 , OR claim 4 , SR claim 4 , Calkyl claim 4 , CH═N—NRR claim 4 , CH=C(NRR) claim 4 , NRCOR claim 4 , NRC(O)NRR claim 4 , aryl claim 4 , and heteroaryl; wherein each R claim 4 , R claim 4 , and Ris independently selected from H and Calkyl.6. The compound of claim 1 , wherein n is 1 and Ris in the para position on the ring.7. The compound of claim 6 , wherein Ris NRR.8. The compound of claim 1 , wherein m is 0 and Ris in the ortho position on the ring.9. The compound of claim 1 , wherein m is 1 and Ris in the ortho position and the Ris in the meta position across the ring from the first R.10. The compound of claim 1 , wherein the HDAC targeting element is selected from the group consisting of: a substituted or unsubstituted aminobenzamide claim 1 , a substituted or unsubstituted hydroxybenzamide claim 1 , and a hydroxamic acid.11. The compound of claim 10 , wherein the HDAC targeting element is selected from the group consisting of: CI-994 claim 10 , Entinostat (MS-275) claim 10 , HDAC1/2 selective CI-994 analog claim 10 , Mocetinostat (MGCD0103) claim 10 , and analogs thereof.15. A method of treating a disorder selected from the group consisting of a proliferative disorder claim 10 , a cancer claim 10 , and a retinal ...

Подробнее
28-01-2016 дата публикации

PPAR AGONISTS

Номер: US20160023991A1
Принадлежит:

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases). 2. The compound of claim 1 , wherein ring B is selected from phenyl claim 1 , pyridine claim 1 , thiophene claim 1 , thiazole claim 1 , pyrazole claim 1 , oxazole claim 1 , isoxazole claim 1 , benzo[b]furan claim 1 , indazole claim 1 , piperidine claim 1 , cyclohexane claim 1 , piperidin-2-one claim 1 , piperazine-2 claim 1 ,5-dione or quinazolin-4(3H)-one.6. The compound of claim 1 , wherein:{'sup': '3', 'Ris selected from aliphatic or alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and/or'}{'sup': 2', '3', '4, 'L, Land Lare each independently selected from a bond or alkylene.'}7. The compound of claim 1 , wherein LRis isopropyl.8. The compound of claim 1 , wherein Ris furan-2-yl or furan-3-yl.11. The compound of claim 1 , wherein the compound is selected from6-(2-((N-isopropyl-[1,1′-biphenyl]-4-carboxamido)methyl)phenoxy)hexanoic acid;ethyl 6-(2-(1-(4-bromo-N-cyclopropylbenzamido)-2-(tert-butylamino)-2-oxoethyl)phenoxy)hexanoate;ethyl 6-(2-(2-(tert-butylamino)-1-(N-cyclopropyl-[1,1′-biphenyl]-4-carboxamido)-2-oxoethyl)phenoxy)hexanoate;ethyl 6-(2-(2-amino-1-(N-cyclopropyl-[1,1′-biphenyl]-4-carboxamido)-2-oxoethyl)phenoxy)hexanoate;6-(2-(2-amino-1-(N-cyclopropyl-[1,1′-biphenyl]-4-carboxamido)-2-oxoethyl)phenoxy)hexanoic acid;6-(2-(2-(tert-butylamino)-1-(N-cyclopropyl-[1,1′-biphenyl]-4-carboxamido)-2-oxoethyl)phenoxy)hexanoic acid;6-(2-((N-cyclopropyl-[1,1′-biphenyl]-4-carboxamido)methyl)phenoxy)hexanoic acid;N-(2-amino-1-(2-((6-(hydroxyamino)-6-oxohexyl)oxy)phenyl)-2-oxoethyl)-N-cyclopropyl-[1,1′-biphenyl]-4-carboxamide;6-(2-((N-cyclopropyl-4-(pyridin-4-yl)benzamido)methyl)phenoxy)hexanoic acid;6-(2-((N-cyclopropyl-4-(pyridin-3-yl)benzamido)methyl)phenoxy)hexanoic acid;6 ...

Подробнее
28-01-2016 дата публикации

INHIBITING NEUROTRANSMITTER REUPTAKE

Номер: US20160024044A1
Принадлежит:

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. Specifically gamma-amino alcohol derivatives that inhibit the reuptake of neurotransmitters such as dopamine, serotonin, epinephrine or norepinephrine are provided as therapeutic agents for the treatment of depression or anxiety in a mammalian subject. 17-. (canceled)9. The compound of claim 8 , wherein Ris optionally substituted with one or two substituents.11. The compound of claim 10 , wherein at least two of R claim 10 , R claim 10 , R claim 10 , R claim 10 , and Rare hydrogen.12. The compound of claim 11 , wherein the remaining R claim 11 , R claim 11 , R claim 11 , R claim 11 , and Rare independently selected from ethyl claim 11 , chloro claim 11 , and bromo.13. The compound of claim 10 , wherein R claim 10 , R claim 10 , and Rare hydrogen; and Rand Rare independently selected from ethyl claim 10 , chloro claim 10 , and bromo.15. The compound of claim 14 , wherein each of Rand Ris not hydrogen.17. The compound of claim 16 , wherein Ris selected from hydrogen claim 16 , lower alkyl claim 16 , halo claim 16 , hydroxyl claim 16 , lower alkoxy claim 16 , methylsulfanyl claim 16 , and methsulfonyl; and Ris selected from hydrogen claim 16 , lower alkyl claim 16 , halo claim 16 , dimethylamino claim 16 , methylsulfanyl claim 16 , and 1 claim 16 ,1 claim 16 ,1-trifluoromethanesulfonamide.1826-. (canceled) This application claims the benefit of U.S. Provisional Application Ser. No. 61/783,122, filed Mar. 14, 2013. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.1. Technical FieldThis document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake.2. Background InformationNeuronal signals are ...

Подробнее
17-04-2014 дата публикации

HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF

Номер: US20140107166A1
Принадлежит: Dana-Farber Cancer Institute, Inc.

The present invention provides novel compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of a compound of the invention to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention. 2. The compound of claim 1 , wherein Rand Rare each H.3. The compound of claim 1 , wherein Ar is a substituted or unsubstituted carbocyclic aryl group having from 6 to 10 atoms in the rings system.4. The compound of claim 1 , wherein Ar is substituted or unsubstituted phenyl.5. The compound of claim 1 , wherein Ar is phenyl substituted L at the position on the phenyl ring para to the —(CRR)—Z moiety.6. The compound of claim 1 , wherein L is a linker having 1-6 atoms.7. The compound of claim 6 , wherein the linker comprises an alkylidene claim 6 , an ether claim 6 , a thioether claim 6 , an amine claim 6 , an amide claim 6 , an ester claim 6 , a carbonate claim 6 , a carbamate claim 6 , or a hydrazone.8. The compound of claim 7 , wherein the linker comprises —(CH)—O— claim 7 , wherein m is an integer from 1 to 4.9. The compound of claim 1 , wherein CAP is a substituted or unsubstituted aryl group.10. The compound of claim 9 , wherein CAP is a substituted or unsubstituted phenyl group.11. The compound of claim 10 , wherein the phenyl group is substituted with 1-5 electron-withdrawing substituents.12. The compound of claim 11 , wherein the 1-5 electron-withdrawing substituents are 1-5 fluorine atoms.13. The compound of claim 1 , wherein Z is —C(O)NHOH.14. The compound of claim 1 , where in n is 1.15. The compound of claim 1 , wherein n is 2 or 3.18. The compound of claim 17 , wherein Ar is a substituted phenyl ...

Подробнее
17-04-2014 дата публикации

Amide derivative, pest control agent containing the amide derivative, and pest controlling method

Номер: US20140107368A1
Принадлежит: Mitsui Chemicals Agro Inc

A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(=G 1 )-Q 1 (wherein G 1 and G 2 represent an oxygen atom or the like, Q 1 represents a phenyl group which may have a substituent, a heterocyclic group which may have a substituent, or the like), or the like, Q 2 represents a phenyl group or the like, G 3 represents an oxygen atom or the like, and R 1 and R 2 each independently represent a hydrogen atom, a C1-C6 alkyl group, or a group represented by -L-D, or the like (provided that at least either R 1 or R 2 represents a group represented by -L-D); as an active ingredient exhibits an excellent effect.

Подробнее
10-02-2022 дата публикации

Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection

Номер: US20220041547A1
Принадлежит: Intervet Inc.

The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD). 2. A compound according to claim 1 , wherein R claim 1 , Rare independently selected from the group consisting of{'sub': 1-6', '2-6', '3-10', '1-6', '1-6', '1', '6', '1', '6', '2, 'sup': 6', '7, 'H, C-alkyl, C-alkenyl, C-cycloalkyl, C-alkyloxy-C-alkyl, C-C-alkyl substituted with aryl, C-C-alkyl substituted with heteroaryl, or NRRis NOor'}{'sup': 6', '7, 'claim-text': {'sup': 6', '7, 'wherein the alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, alkyloxy or the heterocyclic ring formed by R, Rtogether with the N atom to which they are attached is optionally substituted with a substituent selected from the group consisting of'}, 'R, Rtogether with the N atom to which they are attached can form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S, and O;'}{'sub': 1-6', '3-8', '1-6', '1-6', '1-6', '1-6', '1', '6', '2', '2', '1-6, 'sup': 9', '10', '9', '8', '8', '9', '10', '9', '10, 'C-alkyl, C-cycloalkyl, C-alkyloxy, —NRR, carbonyl, —C(═O)—OR, halogen atom, C-alkyl substituted with halo, C-alkyloxy-C-alkyl, aryl, heteroaryl, C-C-alkyl substituted with aryl, cyano, hydroxy, —SR, —SOR, —SONRR, —C(═O)NRR, C-alkyl substituted with hydroxyl.'}3. A compound according to anyone of - claim 1 , wherein L is selected from the group consisting of{'sub': 1-6', '2-6', '2-6', '3-10, 'sup': 'L3', 'C-alkyl, C-alkenyl, C-alkynyl, C-cycloalkyl, —NR—,'} [{'sup': 'L3', 'R, is selected from the group consisting of'}, {'sub': 1-6', '1-6', '1', '6', '1', '6', '1', '6', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'H, C-alkyl, halo-C-alkyl, C-C-alkyl substituted with aryl, C-C-alkyl substituted with heteroaryl, C-C-alkyl substituted with heterocyclyl, preferably wherein L is selected from the group consisting of — ...

Подробнее
02-02-2017 дата публикации

Methionine analogs and methods of using same

Номер: US20170029369A1
Принадлежит: BioXiness Pharmaceuticals Inc

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages.

Подробнее
02-02-2017 дата публикации

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

Номер: US20170029386A9
Принадлежит: Lantheus Medical Imaging, Inc.

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. 150-. (canceled)52. The compound of claim 51 , wherein at least one Ris H.53. The compound of claim 51 , wherein X is N.54. The compound of claim 51 , wherein X is O claim 51 , S claim 51 , or P.55. The compound of claim 51 , wherein:X is N;{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, arylalkyl, and alkylarylalkyl;'}{'sup': 2', '3, 'Rand Rare each independently selected from the group consisting of hydrogen, alkyl, alkylaryl, aryl, arylalkyl, alkylarylalkyl, and heterocyclylalkyl;'}{'sup': '4', 'Ris selected from the group consisting of alkyl, alkylaryl, aryl, arylalkyl, and alkylarylalkyl,'}{'sup': 1', '2', '3', '4', '19', '20', '19', '20', '21', '22', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2, 'wherein each R, R, R, and Ris independently unsubstituted or substituted with one or more of the following: alkyl, alkenyl, cycloalkyl, alkylaryl, alkylcarbonyl, aryl, arylalkyl, alkylarylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, —NRR, —SH, ...

Подробнее
04-02-2016 дата публикации

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20160031876A1
Принадлежит:

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. 5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(O)NH(OH).6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —N(OH)C(O)R.7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , wherein Ris chosen from hydrogen and lower alkyl.8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein Ris lower alkyl.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is 1.10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is 2.11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is 3.12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein claim 1 , for each occurrence claim 1 , Ris independently chosen from halo and lower alkyl.13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is 0.14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris phenyl optionally substituted with 1 to 3 substituents independently chosen from halo claim 1 , alkyl claim 1 , cycloalkyl claim 1 , haloalkyl claim 1 , hydroxyl claim 1 , alkoxy claim 1 , and nitrile.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein Ris phenyl optionally substituted with 1 to 3 substituents independently chosen from halo claim 14 , lower alkyl claim 14 , and haloalkyl.16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof claim 15 , wherein Ris chosen from phenyl claim 15 , 2-fluorophenyl claim 15 , 2-methyl claim 15 , 3-fluoro-2-methylphenyl and 2-methylphenyl.17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof ...

Подробнее
30-01-2020 дата публикации

Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof

Номер: US20200030325A1
Принадлежит:

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. 121-. (canceled)23. The compound of claim 22 , wherein ring A is phenyl claim 22 , naphthyl claim 22 , anthracenyl claim 22 , pyridinyl claim 22 , pyrimidinyl claim 22 , pyrazinyl claim 22 , indolyl claim 22 , imidazolyl claim 22 , oxazolyl claim 22 , furyl claim 22 , thienyl claim 22 , thiazolyl claim 22 , triazolyl claim 22 , isoxazolyl claim 22 , quinolinyl claim 22 , pyrrolyl claim 22 , pyrazolyl claim 22 , or 5 claim 22 ,6 claim 22 ,7 claim 22 ,8-tetrahydroisoquinoline; each of which may be optionally substituted with halo.24. The compound of claim 22 , wherein Ris H claim 22 , methyl claim 22 , ethyl claim 22 , propyl claim 22 , i-propyl claim 22 , butyl claim 22 , i-butyl claim 22 , t-butyl claim 22 , pentyl claim 22 , hexyl claim 22 , phenyl claim 22 , naphthyl claim 22 , pyridinyl claim 22 , OH or OCH; each of which may be optionally substituted with OH claim 22 , halo claim 22 , alkyl claim 22 , or alkoxy.25. The compound of claim 22 , wherein the carbonyl and the Z group attached to ring A are disposed para to each other.26. The compound of claim 22 , wherein the carbonyl and Z group attached to ring A are disposed meta to each other.27. The compound of claim 22 , wherein the carbonyl and the Z group attached to ring A are disposed ortho to each other.29. The compound of claim 28 , wherein ring B is phenyl claim 28 , pyridinyl claim 28 , pyrimidinyl claim 28 , or pyrazinyl; wherein phenyl claim 28 , pyridinyl claim 28 , pyrimidinyl claim 28 , or pyrazinyl may be optionally substituted with alkyl claim 28 , aryl claim 28 , heteroaryl claim 28 , cycloalkyl claim 28 , heterocycloalkyl claim 28 , aralkyl claim 28 , haloalkyl claim 28 , halo claim 28 , OH claim 28 , NH claim 28 , NHR″ claim 28 , CN claim 28 , N claim 28 , or ...

Подробнее
31-01-2019 дата публикации

ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER

Номер: US20190031586A1

An organic compound, a three-dimensional organic structure formed by using the organic compound, a separation sieve and an optical layer having the organic structure, and an optical device having the optical layer as an optical amplification layer are provided. The organic structure includes a plurality of organic molecules self-assembled by non-covalent bonding. Each of the unit organic molecules has an aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of remaining substitutable positions of the aromatic ring. The unit organic molecules are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the first and the second pairs of the substituents and by pi-pi interactions between the aromatic rings. 147-. (canceled)48. A three-dimensional organic structure comprising a plurality of unit organic molecules which are self-assembled to form the three-dimensional organic structure ,wherein each of the unit organic molecules has at least one aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring,{'sub': c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'a', 'c', 'd', 'e', '2, 'wherein the substituents have terminal groups, independently, including a group selected from the group consisting of —CRRR, —OH, —COOH, —CHO, —SH, —COCRRR, —COOCRRR, —CR═CRR, —CN, —N═C═O, —C═N═N—CRRR, —C≡CR, —NHCRRR, or —NH,'}wherein the unit organic molecules contained in one layer of the three-dimensional structure are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the terminal ...

Подробнее
04-02-2021 дата публикации

Imaging histone deacetylases with a radiotracer using positron emission tomography

Номер: US20210030899A1
Принадлежит: General Hospital Corp

wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

Подробнее
05-02-2015 дата публикации

HISTONE DEACETYLASE INHIBITORS

Номер: US20150038581A1
Принадлежит:

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. 1102-. (canceled)104. The method of claim 103 , wherein n is 6.105. The method of claim 103 , wherein m is 1.107. The method of claim 106 , wherein n is 6.108. The method of claim 106 , wherein Ris —C(═O)OR; and Ris methyl claim 106 , ethyl claim 106 , n-propyl claim 106 , isopropyl claim 106 , n-butyl claim 106 , sec-butyl claim 106 , isobutyl claim 106 , tert-butyl claim 106 , n-pentyl claim 106 , sec-pentyl claim 106 , isopentyl claim 106 , tert-pentyl claim 106 , n-hexyl claim 106 , or sec-hexyl.109. The method of claim 108 , wherein Ris ethyl claim 108 , n-propyl claim 108 , isopropyl claim 108 , n-butyl claim 108 , isobutyl claim 108 , or tert-butyl.110. The method of claim 109 , wherein Ris ethyl.111. The method of claim 109 , wherein Ris tert-butyl.115. The method of claim 114 , wherein n is 6.116. The method of claim 114 , wherein m is 1.118. The method of claim 117 , wherein n is 6.119. The method of claim 117 , wherein Ris —C(═O)OR; and Ris methyl claim 117 , ethyl claim 117 , n-propyl claim 117 , isopropyl claim 117 , n-butyl claim 117 , ...

Подробнее
11-02-2016 дата публикации

NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF

Номер: US20160039751A1
Принадлежит: Toyama Chemical Co., Ltd.

A compound represented by general formula (1) (wherein Rrepresents a hydrogen atom, an optionally substituted Calkyl group or the like; Rrepresents a hydrogen atom, an optionally substituted Calkyl group or the like; Rrepresents a hydrogen atom or an optionally substituted Calkyl group; Rrepresents a hydrogen atom, an optionally substituted Calkyl group or the like; Xrepresents an optionally substituted Calkynylene group or the like; A represents an optionally substituted bivalent aromatic hydrocarbon group or the like; Xrepresents an optionally substituted Calkylene group or the like; Yrepresents an oxygen atom or the like; and Rrepresents a hydrogen atom or the like) or a salt thereof is useful as an antibacterial agent. 3. The compound or a salt thereof according to claim 1 , wherein Ris a hydrogen atom or an optionally substituted Calkyl group.4. The compound or a salt thereof according to claim 1 , wherein Ris an optionally substituted Calkyl group.5. The compound or a salt thereof according to claim 1 , wherein Ris a hydrogen atom or an optionally substituted Calkyl group.6. The compound or a salt thereof according to claim 1 , wherein Ris an optionally substituted Calkyl group.7. The compound or a salt thereof according to claim 1 , wherein Ris a hydrogen atom claim 1 , and Ris an optionally substituted Calkyl group.8. The compound or a salt thereof according to claim 1 , wherein Xis an optionally substituted Calkynylene group.9. The compound or a salt thereof according to claim 1 , wherein A is an optionally substituted divalent aromatic hydrocarbon group.10. The compound or a salt thereof according to claim 1 , wherein Yis an oxygen atom.11. The compound or a salt thereof according to claim 1 , wherein Ris a hydrogen atom claim 1 , an optionally substituted Calkyl group claim 1 , an optionally substituted Calkenyl group claim 1 , an optionally substituted Calkynyl group claim 1 , a hydroxyl-protecting group or a thiol-protecting group claim 1 , provided ...

Подробнее
09-02-2017 дата публикации

Hydroxamic acids and uses thereof

Номер: US20170036996A1
Принадлежит: Hawaii Biotech Inc

Compounds of formula I are provided: R 1 is an alkoxy or O(CH 2 ) p X, p is an integer from 2 to 3 and X is OH, NH 2 , or CO 2 H, m is an integer from 0 to 5, n is an integer from 0 to 5, each R 2 is independently selected from hydrogen, alkenyl, hydroxyalkyl, alkoxymethyl, heterocyclyl, hetereocyclylmethyl, amino, amido, hydroxamido, any of which may be optionally substituted with one or more of acyl, alkyl, alkoxy, hydroxyalkyl, or halogen, each R 3 is independently selected from hydrogen, halogen, alkyl, alkenyl, carboxy, hydroxymethyl, amido, and at least one of R 2 and R 3 is not hydrogen.

Подробнее
08-02-2018 дата публикации

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN

Номер: US20180037549A1
Принадлежит:

The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes. 121-. (canceled)25. The compound of formula (XVIII) or (XIX) of claim 22 , wherein Ris 2-methylpropan-oxy.27. The process of claim 26 , wherein Ris an isobutoxy group.34. The process of claim 33 , wherein the compound of formula (V) is prepared by reacting 4-fluorobenzylamine with 1-methylpiperidine-2-one.36. The process of claim 35 , wherein the compound of formula (V) by reacting 4-fluorobenzylamine with 1-methylpiperidine-2-one.38. The process of claim 37 , wherein the compound of formula (V) by reacting 4-fluorobenzylamine with 1-methylpiperidine-2-one. This application claims the benefit of U.S. Provisional Application Nos. 62/126,840, filed Mar. 2, 2015; 62/161,421, filed May 14, 2015; 62/187,668, filed Jul. 1, 2015; 62/188,992, filed Jul. 6, 2015; 62/198,218, filed Jul. 29, 2015; and 62/270,310, filed Dec. 21, 2015, the entireties of which are incorporated by reference herein.The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.Pimavanserin tartrate, 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea L-hemi-tartrate, has the following chemical structure:Pimavanserin tartrate was developed by Acadia Pharmaceuticals and was approved under the trade name NUPLAZID® for use in patients with Parkinson's disease psychosis.Pimavanserin free base and its synthesis are disclosed in U.S. Pat. No. 7,601,740 (referred to herein as US '740 or the '740 patent) and U.S. Pat. No. 7,790,899 (referred to herein as US '899 or the '899 patent). US '740 discloses the synthesis of Pimavanserin free base (also referred to herein as “Compound A”), which includes O-alkylation followed by ester hydrolysis, and then in situ azidation. This ...

Подробнее
07-02-2019 дата публикации

NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF

Номер: US20190040004A1
Принадлежит:

Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof. 2. Compound of formula (I′) according to claim 1 , wherein Ar is chosen fromi) a phenyl substituted at the meta-, para-, or ortho-position by a fluor or a thiazolyl, orii) a benzyl substituted at the meta-position by an C1 to C4 alkoxy group.9. A method for treating claim 1 , inhibiting or preventing a parasitic disease in a mammalian subject claim 1 , including human claim 1 , cat or dog claim 1 , comprising applying an effective amount of the compound of formula (I′) of in the form of a pharmaceutical drug.10TrypanosomaLeishmaniaToxoplasma gondii.. The method of claim 9 , wherein the parasitic disease is caused by a protozoan parasite of the family of the Trypanosomatidae selected from the genus or the genus claim 9 , or the parasite11. A method for treating toxoplasmosis claim 4 , comprising applying an effective amount of the compound of formula (Ia1) of in the form of a pharmaceutical drug.12. A pharmaceutical composition comprising a compound of formula (I′) according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutical acceptable excipient.13. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a compound of formula (I′) according , or a pharmaceutically acceptable salt thereof, and'}at least one anti-parasitic compound, selected from the group comprising: miltefosin, antimony based drugs, like meglumine antimoniate or sodium stibogluconate, amphotericin B, benzimidazol, nifurtimox, paromomycin, pentamidin and its derivatives, arsenic derivatives, melarsoprol and difluoromethylornithin.16. The compound of claim 1 , wherein Ar is a phenyl.17. The compound of claim 1 , wherein Ar is a benzyl.18. The compound of claim 1 , wherein the halogen is a fluor atom.19. The compound of claim 1 , wherein the halogen is a thiazolyl.20. The ...

Подробнее
12-02-2015 дата публикации

Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8

Номер: US20150045367A1
Принадлежит: Pharmacyclics LLC

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.

Подробнее
12-02-2015 дата публикации

Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof

Номер: US20150045380A1
Принадлежит: Acetylon Pharmaceuticals Inc

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.

Подробнее
15-02-2018 дата публикации

ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS

Номер: US20180044282A1
Принадлежит:

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors. 116-. (canceled)17. A method of treating cancer , neurological disease , inflammatory disease , autoimmune disease , infection , metabolic disease , hematological disease , or cardiovascular disease in a subject in need thereof , comprising administering to the subject an effective amount of a compound selected from:(E)-3-(2-((1H-benzo[d]imidazol-2-yl)amino)phenyl)-N-hydroxyacrylamide (I-1);(E)-N-hydroxy-3-(2-(((1-(2-methoxyethyl)-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)acrylamide (I-2);(E)-N-hydroxy-3-(2-((1-(2-methoxyethyl)-1H-benzo[d]imidazol-2-yl)amino)phenyl)acrylamide (I-3);(E)-N-hydroxy-3-(2-(((6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)acrylamide (I-4);(E)-N-hydroxy-3-(2-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl)acrylamide (I-5);(E)-1-hydroxy-N-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)cyclobutane-1-carboxamide (I-6);(E)-N-hydroxy-3-(2-((3-(trifluoromethyl)phenyl)sulfonamido)phenyl)acrylamide (I-7);(E)-3-(2-(4-aminopiperidin-1-yl)phenyl)-N-hydroxyacrylamide (I-8);(E)-N-hydroxy-3-(2-(4-(2-(4-methoxyphenyl)acetamido)piperidin-1-yl)phenyl)acrylamide (I-9);(E)-3-(2-(4-(2-(4-chlorophenoxy)acetamido)piperidin-1-yl)phenyl)-N-hydroxyacrylamide (I-10);(E)-N-(1-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)piperidin-4-yl)-1,8-naphthyridine-2-carboxamide (I-11);(E)-N-(1-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)piperidin-4-yl)-1-methylazetidine-3-carboxamide (I-12);(E)-3-(2-(4-(2-(4-chlorophenyl)acetamido)piperidin-1-yl)phenyl)-N-hydroxyacrylamide (I-13);(E)-N-(1-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)piperidin-4-yl)-3-methylbenzamide (I-14);(E)-5-(4-chlorophenyl)-N-(1-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)piperidin-4-yl)-2-methylfuran-3-carboxamide (I-15);(E)-N-(1-(2-(3-( ...

Подробнее
23-02-2017 дата публикации

HDAC8 INHIBITORS FOR TREATING CANCER

Номер: US20170050922A2
Принадлежит:

Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8. 138.-. (canceled)40. The compound of claim 39 , wherein X is —C(R)—.41. The compound of claim 39 , wherein Ris halogen claim 39 , —CF claim 39 , —OR claim 39 , —NO claim 39 , substituted or unsubstituted alkyl claim 39 , or substituted or unsubstituted heteroalkyl.42. The compound of claim 39 , wherein Ris hydrogen claim 39 , halogen claim 39 , or —OR.43. The compound of claim 39 , wherein Y is a bond or —N(R)—.44. The compound of claim 39 , wherein Lis a bond claim 39 , —C(O)— claim 39 , —O— claim 39 , —NH— claim 39 , substituted or unsubstituted alkylene claim 39 , substituted or unsubstituted heteroalkylene claim 39 , substituted or unsubstituted cycloalkylene claim 39 , substituted or unsubstituted heterocycloalkylene claim 39 , substituted or unsubstituted arylene claim 39 , or substituted or unsubstituted heteroarylene.45. The compound of claim 39 , wherein Ris halogen claim 39 , —CF claim 39 , —NO claim 39 , —NH claim 39 , —OR claim 39 , substituted or unsubstituted alkyl claim 39 , substituted or unsubstituted heteroalkyl claim 39 , substituted or unsubstituted cycloalkyl claim 39 , substituted or unsubstituted heterocycloalkyl claim 39 , substituted or unsubstituted aryl claim 39 , or substituted or unsubstituted heteroaryl.46. The compound of claim 39 , wherein Ris{'sup': 11', '10', '10', '10', '10', '10, 'R-substituted or unsubstituted alkyl, R-substituted or unsubstituted heteroalkyl, R-substituted or unsubstituted cycloalkyl, R-substituted or unsubstituted heterocycloalkyl, R-substituted or unsubstituted aryl, or R-substituted or unsubstituted heteroaryl; and wherein'}{'sup': '10', 'sub': 3', '3', '3', '3', '3', '3', '2', '3', '2', '2', '2', '2', '2', '2', '2, 'Ris hydrogen, halogen, —N, —CF, —CCl, —CBr, —CI, —CN, —C(O)H, —OCH, —OCHCH, —NH, —COOH, —CONH, —NO, —SH, —S(O)H, —NHNH, —ONH, —NHC(O)NHNH, substituted or unsubstituted heteroalkyl, substituted or ...

Подробнее
10-03-2022 дата публикации

ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS

Номер: US20220073452A1
Принадлежит:

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors. 139-. (canceled)41. The method of claim 40 , wherein Rand Rare combined to form a heterocycle claim 40 , wherein said heterocycle is optionally substituted with one or more R.42. The method of claim 41 , wherein Ris at least one of hydrogen claim 41 , C-Calkyl claim 41 , oxo claim 41 , or C-Ccycloalkyl.43. The method of claim 41 , wherein Ris at least one of hydrogen claim 41 , oxo claim 41 , C-Ccycloalkyl claim 41 , or two Rwhen attached to the same carbon atom can form a C-Cspirocycle or a 3- to 12-membered spiroheterocycle.44. The method of claim 40 , wherein Ris aryl claim 40 , optionally substituted with one or more R.45. The method of claim 44 , wherein Ris —OR.46. The method of claim 40 , wherein the compound is (E)-N-(2-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)-2-phenoxybenzamide claim 40 , or a pharmaceutically acceptable salt thereof.47. The method according to claim 40 , wherein the disease or disorder associated with HDAC8 inhibition is cancer claim 40 , neurological disease claim 40 , inflammatory disease claim 40 , autoimmune disease claim 40 , infection claim 40 , metabolic disease claim 40 , hematological disease claim 40 , or cardiovascular disease.48. The method according to claim 47 , wherein the cancer is colon cancer claim 47 , lung cancer claim 47 , neuroblastoma claim 47 , ovarian cancer claim 47 , hepatocellular carcinoma claim 47 , gastric cancer claim 47 , prostate cancer claim 47 , pancreatic cancer claim 47 , renal cancer claim 47 , cervical cancer claim 47 , ovarian cancer claim 47 , head and neck cancer claim 47 , lymphoma claim 47 , colorectal cancer claim 47 , non-small cell lung carcinoma claim 47 , breast cancer claim 47 , bladder cancer claim 47 , acute myeloid leukemia claim 47 , acute lymphoblastic ...

Подробнее
21-02-2019 дата публикации

PRODRUGS OF PHENOLIC TRPV1 AGONISTS

Номер: US20190055272A1
Принадлежит:

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity. 4. The compound of or , wherein m is 1.5. The compound of any one of - , wherein X is —O—.6. The compound of any one of - , wherein X is —N(R)—.7. The compound of any one of - , wherein X is NH.8. The compound of or , wherein m is 0.9. The compound of any one of - , wherein Rand Rare independently selected from hydrogen and unsubstituted Calkyl.10. The compound of any one of - , wherein Rand Rare hydrogen.13. The compound of claim 12 , wherein A is O.14. The compound of any one of - claim 12 , wherein Ris independently selected from unsubstituted Calkyl claim 12 , —Calkyl-OH claim 12 , —Calkyl-C(═O)OH claim 12 , —Calkyl-C(═O)NH claim 12 , —Calkyl-N(H)C(═NH)NH claim 12 , —Calkyl-(phenyl) claim 12 , —Calkyl-(4-hydroxyphenyl) claim 12 , and —Calkyl-(heteroaryl).15. The compound of any one of - claim 12 , wherein Rand Rare independently selected from hydrogen and unsubstituted Calkyl.16. The compound of any one of - claim 12 , wherein Rand Rare hydrogen.17. The compound of any one of - claim 12 , wherein n is 1.18. The compound of any one of - claim 12 , wherein n is 2.21. The compound of claim 20 , wherein each A is O.22. The compound of or claim 20 , wherein each Z is —O—.23. The compound of or claim 20 , wherein each Z is —N(R)—.24. The compound of claim 23 , wherein each Ris independently hydrogen or unsubstituted Calkyl.25. The compound of any one of - claim 23 , wherein each Rand Rare independently selected from hydrogen claim 23 , and unsubstituted or substituted Calkyl.26. The compound of any one of - claim 23 , wherein each n is 1.27. The compound of any one of - claim 23 , wherein each n is 2.30. The compound of or claim 23 , wherein Rand Rare hydrogen.31. The compound of any one of - claim 23 , wherein n is 1.32. The compound of any one of - ...

Подробнее
01-03-2018 дата публикации

Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity

Номер: US20180057448A1
Автор: Pflum Mary Kay
Принадлежит:

A compound having formula I for histone deacetylase inhibition is provided: 2. The compound of wherein R is Calkyl or Caryl claim 1 , Cheteroaryl claim 1 , and Calkylaryl.3. The compound of wherein R is methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , isopropyl claim 1 , butyl claim 1 , isobutyl claim 1 , tert-butyl claim 1 , pentyl claim 1 , hexyl claim 1 , or octyl.4. The compound of wherein R is ethenyl claim 1 , propenyl claim 1 , butenyl claim 1 , pentenyl claim 1 , hexenyl claim 1 , octenyl claim 1 , or butadienyl or allenyl.5. The compound of wherein R is ethynyl claim 1 , propynyl claim 1 , butynyl claim 1 , pentynyl claim 1 , hexynyl claim 1 , or heptynyl.6. The compound of wherein R is benzyl.7. The compound of wherein the carbon atom labeled by * is R.8. The compound of wherein the carbon atom labeled by * is S.10. The pharmaceutical composition of wherein R is Calkyl claim 9 , Caryl claim 9 , Cheteroaryl claim 9 , Calkylaryl claim 9 , Calkylheteroaryl claim 9 , or halo.11. The compound of wherein R is Calkyl or Caryl claim 1 , Cheteroaryl claim 1 , and Calkylaryl.12. The pharmaceutical composition of wherein R is methyl claim 9 , ethyl claim 9 , n-propyl claim 9 , isopropyl claim 9 , butyl claim 9 , isobutyl claim 9 , tert-butyl claim 9 , pentyl claim 9 , hexyl claim 9 , or octyl.13. The pharmaceutical composition of wherein R is ethenyl claim 9 , propenyl claim 9 , butenyl claim 9 , pentenyl claim 9 , hexenyl claim 9 , octenyl claim 9 , or butadienyl or allenyl.14. The pharmaceutical composition of wherein R is ethynyl claim 9 , propynyl claim 9 , butynyl claim 9 , pentynyl claim 9 , hexynyl claim 9 , or heptynyl.15. The pharmaceutical composition of wherein R is benzyl.16. The pharmaceutical composition of comprising 5 to about 75 percent of the compound having formula I combined.17. The pharmaceutical composition of wherein the pharmaceutically acceptable carrier is selected from the group consisting of magnesium carbonate claim 9 , magnesium ...

Подробнее
22-05-2014 дата публикации

METHIONINE ANALOGS AND METHODS OF USING SAME

Номер: US20140142189A1
Принадлежит: BIOXINESS PHARMACEUTICALS, INC.

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages. 1151-. (canceled)153. The compound of claim 152 , wherein Y is S.154. The compound of claim 152 , wherein Y is O.155. The compound of claim 152 , wherein m is 1 or 2.156. The compound of claim 152 , n is 0 claim 152 , 1 claim 152 , or 2.157. The compound of claim 152 , wherein p is 0 claim 152 , 1 claim 152 , or 2.158. The compound of claim 152 , wherein the amino acid moiety is selected from the group consisting of glycine claim 152 , alanine claim 152 , lysine claim 152 , methionine claim 152 , and proline.159. The compound of claim 158 , wherein the amino acid moiety claim 158 , when substituted claim 158 , has one or more substituents independently selected from the group consisting of alkyl claim 158 , thiol claim 158 , and sulfonyl.160. The compound of claim 152 , wherein Ris linked to the parent structure through an amide bond.161. The compound of claim 152 , wherein w is 0 or 1.162. The compound of claim 152 , wherein Y is S; and w is 0.163. The compound of claim 162 , wherein C is unsubstituted or substituted glycine.164. The compound of claim 152 , wherein Y is S; and w is 1.165. The compound of claim 164 , wherein B is unsubstituted glycine; and C is unsubstituted glycine.167. The compound of claim 152 , wherein Rhydrogen or unsubstituted or substituted alkyl claim 152 , wherein when substituted claim 152 , the alkyl has one or more substituents independently selected from the group consisting of halo and amino.168. The compound of claim 152 , wherein Ris unsubstituted alkyl.169. The compound of claim 168 , wherein Ris methyl.170. A formulation ...

Подробнее
28-02-2019 дата публикации

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20190062321A1
Принадлежит:

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. 151.-. (canceled)53. (canceled)54. The method of claim 52 , wherein said at least one histone deacetylase is HDAC4.55. The method of claim 52 , wherein said condition or disorder involves a neurodegenerative pathology.56. The method of claim 52 , wherein said condition or disorder is Huntington's disease.64. A method for treating a condition or disorder mediated by at least one histone deacetylase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound claim 52 , or a pharmaceutically acceptable salt thereof claim 52 , selected from:(S)-5-(3-Fluoro-2-methylphenyl)-N-hydroxy-1-phenyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-5-(3-Fluoro-2-methylphenyl)-N-hydroxy-1-(o-tolyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-5-(3-Fluoro-2-methyl phenyl)-1-(2-fluorophenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-1-(3-Chlorophenyl)-5-(3-fluoro-2-methylphenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-5-(3-Fluoro-2-methylphenyl)-1-(4-fluorophenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-5-(3-Fluoro-2-methylphenyl)-1-(3-fluorophenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-1-(2-Chlorophenyl)-5-(3-fluoro-2-methylphenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-1-(4-Chlorophenyl)-5-(3-fluoro-2-methylphenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-5-(3-Fluoro-2-methyl phenyl)-N-hydroxy-1-(p-tolyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-1-(3-Chloro-2-fluorophenyl)-5-(3-fluoro-2-methylphenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-5-carboxamide;(S)-1-(2,6-Difluorophenyl)-5-(3-fluoro-2-methylphenyl)-N-hydroxy-1,4,5,6-tetrahydrocyclopenta[ ...

Подробнее
09-03-2017 дата публикации

NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE

Номер: US20170066712A1
Принадлежит:

This invention provides a compound having the structure: 135-. (canceled)43. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.44. A method of inhibiting the activity of a histone deactylase in a cell claim 37 , the method comprising contacting the histone deacetylase with the compound of so as to inhibit the activity of the histone deacetylase; or of increasing accumulation of acetylated alpha tubulin in a cell claim 37 , the method comprising contacting the cell with the compound of so as to increase the accumulation of acetylated alpha-tubulin in the cell.50. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.51. A method of inhibiting the activity of a histone deactylase in a cell claim 45 , the method comprising contacting the histone deacetylase with the compound of so as to inhibit the activity of the histone deacetylase; or of increasing accumulation of acetylated alpha tubulin in a cell claim 45 , the method comprising contacting the cell with the compound of so as to increase the accumulation of acetylated alpha-tubulin in the cell.53. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.54. A method of inhibiting the activity of a histone deactylase in a cell claim 52 , the method comprising contacting the histone deacetylase with the compound of so as to inhibit the activity of the histone deacetylase; or of increasing accumulation of acetylated alpha tubulin in a cell claim 52 , the method comprising contacting the cell with the compound of so as to increase the accumulation of acetylated alpha-tubulin in the cell. This application claims priority of U.S. Provisional Application No. 61/620,783, filed Apr. 5, 2012 and 61/542,598, filed Oct. 3, 2011, the contents of each of which are hereby incorporated by reference.Throughout this application, certain publications are referenced in parentheses. Full citations for ...

Подробнее
09-03-2017 дата публикации

LXR AGONISTS AND USES THEREOF

Номер: US20170066791A1
Принадлежит:

This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer. 2. The compound of claim 1 , wherein c is 0.3. The compound of claim 1 , wherein b is 1.4. The compound of claim 1 , wherein b is 0.5. The compound of claim 1 , wherein each Rand Ris hydrogen.6. The compound of claim 1 , wherein Ris hydrogen.7. The compound of claim 1 , wherein Ris fluorine.8. The compound of claim 1 , wherein Ris optionally substituted C-Calkyl.9. The compound of claim 8 , wherein said optionally substituted C-Calkyl is methyl10. The compound of claim 1 , wherein Ris phenyl or 4-fluorophenyl.11. The compound of claim 1 , wherein Ris hydrogen claim 1 , halogen claim 1 , optionally substituted C-Caryl claim 1 , optionally substituted C-Ccycloalkyl claim 1 , or optionally substituted C-Calkyl.12. The compound of claim 11 , wherein Ris hydrogen claim 11 , fluorine claim 11 , phenyl claim 11 , cyclohexyl claim 11 , or methyl.13. The compound of claim 12 , wherein Ris hydrogen claim 12 , phenyl claim 12 , or methyl.14. The compound of claim 1 , wherein d is 1.15. The compound of claim 1 , wherein each Rand Ris hydrogen.19. The compound of claim 1 , wherein B is optionally substituted C-Caryl.20. The compound of claim 19 , wherein said optionally substituted C-Caryl is 2-chloro-3-trifluoromethyl-phenyl claim 19 , 2-fluoro-3-trifluoromethyl-phenyl claim 19 , 3-(1 claim 19 ,1 claim 19 ,2 claim 19 ,2-tetrafluoroethoxy)-phenyl claim 19 , 3-trifluoromethyl-phenyl claim 19 , 3-trifluoromethyl-4-fluoro-phenyl claim 19 , 3-trifluoromethoxy-phenyl claim 19 , or 2 claim 19 ,2-difluoro-1 claim 19 ,3-benzodioxole.21. The compound of claim 20 , wherein B is 2-chloro-3-trifluoromethyl-phenyl claim 20 , 2-fluoro-3-trifluoromethyl-phenyl claim 20 , or 3-trifluoromethyl-phenyl.22. The compound of claim ...

Подробнее
07-03-2019 дата публикации

Photoswitchable HDAC Inhibitors

Номер: US20190070295A1
Принадлежит: General Hospital Corp

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

Подробнее
19-03-2015 дата публикации

N-alkoxyamide conjugates as imaging agents

Номер: US20150078997A1
Принадлежит: Lantheus Medical Imaging Inc

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Подробнее
18-03-2021 дата публикации

SYSTEM FOR PRODUCING REMOTE SENSING DATA FROM NEAR EARTH ORBIT

Номер: US20210078942A1
Принадлежит:

A satellite system operates at altitudes between 180 km and 350 km relying on vehicles including an engine to counteract atmospheric drag to maintain near-constant orbit dynamics. The system operates at altitudes that are substantially lower than traditional satellites, reducing size, weight and cost of the vehicles and their constituent subsystems such as optical imagers, radars, and radio links. The system can include a large number of lower cost, mass, and altitude vehicles, enabling revisit times substantially shorter than previous satellite systems. The vehicles spend their orbit at low altitude, high atmospheric density conditions that have heretofore been virtually impossible to consider for stable orbits. Short revisit times at low altitudes enable near-real time imaging at high resolution and low cost. At such altitudes, the system has no impact on space junk issues of traditional LEO orbits, and is self-cleaning in that space junk or disabled craft will de-orbit. 1. A satellite configured to maintain an orbit between 180 km and 350 km , the satellite being one of a plurality of satellites in a satellite system , the satellite comprising:a vehicle bus comprising:a frontal section having at least one beveled surface configured to reduce drag; anda material applied to at least a portion of the at least one beveled surface to provide at least partial specular reflection of incident atmospheric particles, the at least one beveled surface and the material configured to reduce drag on and damage to the material from interactions with atmospheric particles incident to at least one of the satellites of the plurality of satellites during orbit by the partial specular reflection of the atmospheric particles.2. The satellite defined in claim 1 , wherein the at least one beveled surface and the material are configured to reduce drag on the frontal section by more than 25 percent compared to the same frontal section geometry with a material that results in fully diffuse ...

Подробнее
12-06-2014 дата публикации

Histone deacetylase inhibitors and compositions and methods of use thereof

Номер: US20140163009A1
Принадлежит: CHDI Foundation Inc

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

Подробнее
30-03-2017 дата публикации

ANTIBACTERIAL AGENTS

Номер: US20170088549A1
Принадлежит:

Antibacterial compounds of formula (I) are provided: 2. A compound of wherein G is selected from the group consisting of:(1) —C≡C—,(2) —C≡C—C≡C—,{'sup': 3G', '3G, '(3) —CR═CR—C≡C—, and'}{'sup': 3G', '3G, '(4) —C≡C—CR═CR—.'}3. A compound of wherein G is selected from the group consisting of:(1) —C≡C—,(2) —C≡C—C≡C—,(3) —CH═CH—C≡C—, and(4) —C≡C—CH═CH—.4. A compound of wherein G is —C≡C—.5. A compound of wherein G is —C≡C—C≡C—.6. A compound of wherein G is —CH═CH—C≡C—.8. A compound of wherein G is —C≡C—CH═CH—.10. A compound of any one of - wherein X is —(C═O)NR—.11. A compound of wherein X is —(C═O)NH—.12. A compound of any one of - wherein Q is —(C═O)N(R claim 10 ,R).13. A compound of wherein Q is —(C═O)NHOH.14. A compound of any one of - wherein n is 0.15. A compound of any one of - wherein Ris H.16. A compound of any one of - wherein Y is substituted or unsubstituted aryl.17. A compound of wherein Y is substituted or unsubstituted phenyl.18. A compound of wherein Y is unsubstituted phenyl.19. A compound of any one of - wherein A is selected from the group consisting of:{'sub': 2', '0-4', '2', '0-4, 'sup': 1a', '2a', '3a, '(1) —(CH)C(R,R)(CH)OR,'}{'sub': 2', '0-4, 'sup': 1a', '2a', '4a', '5a, '(2) —(CH)C(R,R)N(R,R), and'}{'sup': 1a', '2a, '(3) —CH(R,R).'}20. A compound of wherein A is selected from the group consisting of —CH(CH) claim 19 , —CHOH claim 19 , —CHNH claim 19 , —CHCHOH claim 19 , —CHCHNHand —C(CH)OH.21. A compound of wherein A is —C(CH)NH.22. A compound of any one of - wherein A is selected from the group consisting of:{'sub': 3', '10, '(1) substituted or unsubstituted C-C-cycloalkyl,'}(2) substituted or unsubstituted aryl,(3) substituted or unsubstituted heterocyclyl, and(4) substituted or unsubstituted heteroaryl.26. A compound of any one of - wherein D is present.27. A compound of wherein D is substituted or unsubstituted heteroaryl.29. A compound of wherein D is substituted or unsubstituted aryl.30. A compound of wherein D is substituted or ...

Подробнее
02-04-2015 дата публикации

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

Номер: US20150094465A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. 2. A compound as in claim 1 , wherein X is nitrogen.3. A compound as in claim 1 , wherein X is oxygen.4. A compound as in claim 1 , wherein X is sulfur.5. A compound as in claim 1 , wherein X is phosphorus.6. A compound as in claim 1 , wherein:X is nitrogen;{'sup': '1', 'Ris hydrogen, alkyl, arylalkyl, or alkylarylalkyl;'}{'sup': 2', '3, 'Rand Rcan be the same or different and are hydrogen, alkyl, alkylaryl, aryl, arylalkyl, alkylarylalkyl, or heterocyclylalkyl;'}{'sup': '4', 'Ris alkyl, alkylaryl, aryl, arylalkyl, or alkylarylalkyl,'}{'sup': 1', '2', '3', '4, 'wherein at least one of R, R, R, and Ris substituted with a chelator moiety;'}9. A compound as in claim 8 , whereinn is 1 or 2;{'sup': 'y', 'Ris hydrogen; and'}{'sup': 'z', 'Ris selected from alkyl, aryl, cycloalkyl, and heteroaryl.'}10. A compound as in claim 1 , wherein Rcomprises the at least one chelator moiety.11. A compound as in claim 1 , wherein Ror Rcomprises the at least one chelator moiety.12. A compound as in claim 1 , wherein Rcomprises the at least one chelator moiety.18. A compound as in claim 17 , wherein one of Dand Dis a hydrogen and the other is a chelator moiety.20. A compound as in claim 19 , whereino, r, s, t, and u are each 1; andp and ...

Подробнее
13-04-2017 дата публикации

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20170101402A1
Принадлежит:

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein. 3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Ris chosen from phenyl optionally substituted with one or two substituents independently chosen from lower alkyl claim 2 , lower haloalkyl claim 2 , lower alkoxy claim 2 , lower haloalkoxy claim 2 , and halo.4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein Ris chosen from phenyl claim 3 , 2-methylphenyl claim 3 , 3-methylphenyl claim 3 , 4-methylphenyl claim 3 , 2-fluorophenyl claim 3 , 3-fluorophenyl claim 3 , 4-fluorophenyl claim 3 , 2-chlorophenyl claim 3 , 3-chlorophenyl claim 3 , 4-chlorophenyl claim 3 , 3-chloro-2-fluorophenyl claim 3 , 2 claim 3 ,6-difluorophenyl claim 3 , 2 claim 3 ,5-dimethylphenyl claim 3 , 2 claim 3 ,6-dimethylphenyl claim 3 , 2-chloro-6-fluorophenyl claim 3 , 2-fluoro-6-methylphenyl claim 3 , 2 claim 3 ,4-difluorophenyl claim 3 , 4-(difluoromethoxy)phenyl claim 3 , and 3-fluoro-2-methylphenyl.5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Ris chosen from pyridin-2-yl claim 2 , pyridin-4-yl claim 2 , and pyrazin-2-yl claim 2 , each of which is optionally substituted with one or two substituents independently chosen from lower alkyl and halo.6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein Ris chosen from 5-fluoropyridin-2-yl claim 5 , pyrazin-2-yl claim 5 , and 3- ...

Подробнее
04-04-2019 дата публикации

NOVEL IMAGING COMPOSITION AND USES THEREOF

Номер: US20190099392A1
Принадлежит:

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours. 115-. (canceled)17. The conjugate of claim 16 , wherein L is OR.18. The conjugate of claim 17 , wherein R is Cto Calkyl.19. The conjugate of claim 17 , wherein OR is selected from O-p-toluenesulfonate claim 17 , O-methanesulfonate claim 17 , O-trifluoromethanesulfonate claim 17 , O-benzenesulfonate claim 17 , and O-m-nitrobenzenesulfonate.20. The conjugate of claim 16 , wherein the target molecule is a polypeptide.21. The conjugate of claim 20 , wherein the polypeptide is an antibody.22. The conjugate of claim 21 , wherein the antibody is selected from trastuzumab claim 21 , rituximab and cetuximab.23. The conjugate of claim 16 , wherein the target molecule is a peptide.24. The conjugate of claim 23 , wherein the peptide is a targeting peptide.25. The conjugate of claim 24 , wherein the targeting peptide is selected from a cyclic RGD sequence claim 24 , bombesin and glu-N(CO)N-lys PSMA. The present invention relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours. The present invention also relates to compositions including the compounds, and to methods of imaging patients using the compounds.Zirconium-89 (Zr) is a positron-emitting radionuclide that is used in medical imaging applications. In particular, it is used in positron emission tomography (PET) for cancer detection and imaging. It has a longer half-life (t=79.3 hours) than other radionuclides used for medical imaging, such as F. For example, F has a tof 110 minutes, which means that its use requires close proximity to a cyclotron facility and rapid and high-yielding synthesis techniques for the preparation of the agents into which it is incorporated. Zr is not plagued by these same problems, which makes ...

Подробнее
11-04-2019 дата публикации

HYDROXAMIC ACID TYPE CONTRAST AGENT CONTAINING RADIOISOTOPE FLUORIDE, PREPARATION METHOD AND APPLICATION THEREOF

Номер: US20190106381A1
Принадлежит:

The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III): 14-. (canceled)6. (canceled)7. The method for preparing a hydroxamic acid-based contrast agent containing an isotope of fluorine according to claim 5 , wherein the fluorination is chemically labeling with the isotope Fluorine-18 or the isotope Fluorine-19.8. The method for preparing a hydroxamic acid-based contrast agent containing an isotope of fluorine according to claim 5 , wherein the fluorination comprises reacting absolute Fluorine-18 with the precursor for 10-30 min at 100-120° C.910-. (canceled) This application also claims priority to Taiwan Patent Application No. 106134788 filed in the Taiwan Patent Office on Oct. 11, 2017, the entire content of which is incorporated herein by reference.The present disclosure relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, and more particularly to a contrast agent useful in the diagnosis of spinocerebellar ataxia.In August, 2000, Rare Disease Control and Orphan Drug Act was promulgated, in which associated regulations about rare diseases were formulated. By Dec. 31, 2015, the National Health Department, Ministry of Health and Welfare Department of the Executive Yuan announced a total of 205 rare diseases. Spinocerebellar ataxia is one of the rare genetic diseases, and included in the major injury and disease category 07, with a rare disease classification serial number 334.3. The prevalence of spinocerebellar ataxia varies from species to species and from country to country. The incidence in the United States is estimated to be about 3-5 cases in every 100,000 people, and about 10 thousands of people suffer from spinocerebellar ataxia in Taiwan, constituting the largest population among all the people with various rare diseases.At present, there is no effective diagnosis and treatment for spinocerebellar ataxia, and ...

Подробнее
11-04-2019 дата публикации

METHOD OF CONVERTING A NITRILE FUNCTIONAL GROUP INTO A HYDROXAMIC FUNCTIONAL GROUP BY USING A PEROXOCOBALT COMPLEX AT ROOM TEMPERATURE AND NORMAL PRESSURE

Номер: US20190106382A1
Автор: Cho Jaeheung, Noh Hyeon Ju

The method of the present invention for converting a nitrile functional group into a hydroxamic acid functional group can be easily performed at room temperature and under normal pressure by using a peroxocobalt complex. The final hydroxamic acid functional group produced through the intermediate Hydroximatocobalt (III) compound or the derivative comprising the same has been known to be able to inhibit the growth of cancer cells, so that the conversion method of the present invention can be applied to the preparation of a pro-drug for anticancer treatment. 2. The method according to claim 1 , wherein the Rand Rabove are independently t-butyl or cyclohexyl.4. The method according to claim 3 , wherein the aliphatic hydrocarbon group is straight Calkyl claim 3 , branched Calkyl claim 3 , substituted Ccycloalkyl claim 3 , or unsubstituted Ccycloalkyl claim 3 , and wherein the substituted Ccycloalkyl is a Ccycloalkyl substituted with one or more substituents claim 3 , wherein the one or more substituents are halogen claim 3 , —OH claim 3 , —CN claim 3 , —NO claim 3 , straight Calkyl claim 3 , branched Calkyl straight Calkoxy or branched Calkoxy; and{'sub': '6-10', 'wherein the aromatic hydrocarbon group is substituted or unsubstituted Caryl, and'}{'sub': 6-10', '6-10', '2', '1-5', '1-5', '1-5', '1-5, 'wherein the substituted Caryl is Caryl substituted with one or more substituents, wherein the one or more substituents are halogen, —OH, —CN, —NO, straight Calkyl, branched Calkyl, straight Calkoxy, or branched Calkoxy.'}5. The method according to claim 3 , wherein the aliphatic hydrocarbon group is straight Calkyl claim 3 , branched Calkyl claim 3 , substituted Ccycloalkyl claim 3 , or unsubstituted Ccycloalkyl claim 3 , and wherein the substituted Ccycloalkyl is Ccycloalkyl substituted with one or more substituents claim 3 , wherein the one or more substituents are straight Calkyl claim 3 , branched Calkyl claim 3 , straight Calkoxy claim 3 , or branched Calkoxy; and ...

Подробнее
13-05-2021 дата публикации

RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING

Номер: US20210138096A1
Принадлежит:

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample. 125.-. (canceled)27. The compound of claim 26 , wherein the antibody or antigen-binding fragment thereof has one or more properties selected from the group consisting of:{'sub': 'D', '(a) binds monomeric human LAG3 with a binding dissociation equilibrium constant (K) of less than about 8 nM as measured in a surface plasmon resonance assay at 37° C.;'}{'sub': 'D', '(b) binds monomeric human LAG3 with a Kless than about 10 nM in a surface plasmon resonance assay at 25° C.;'}{'sub': 'D', '(c) binds dimeric human LAG3 with a Kof less than about 1 nM as measured in a surface plasmon resonance assay at 37° C.; and'}{'sub': 'D', '(d) binds dimeric human LAG3 with a Kless than about 1.1 nM in a surface plasmon resonance assay at 25° C.'}28. (canceled)29. The compound of claim 26 , wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs) within the heavy chain variable region (HCVR)/light chain variable region (LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 2/10 claim 26 , 18/26 claim 26 , 34/42 claim 26 , 50/58 claim 26 , 66/74 claim 26 , 82/90 claim 26 , 98/106 claim 26 , 114/122 claim 26 , 130/138 claim 26 , 146/154 claim 26 , 162/170 claim 26 , 178/186 claim 26 , 194/202 claim 26 , 210/218 claim 26 , 226/234 claim 26 , 242/250 claim 26 , 258/266 claim 26 , 274/282 claim 26 , 290/298 claim 26 , 306/314 claim 26 , 322/330 claim 26 , 338/346 claim 26 , 354/362 claim 26 , 370/378 claim 26 , 386/394 claim 26 , 402/410 claim 26 , 418/426 claim 26 , 434/442 claim 26 , 450/522 claim 26 , 458/522 claim 26 , 466/522 claim 26 , 474/522 claim 26 , 482/522 claim 26 , 490/522 claim 26 , 498/530 claim 26 , 506/530 claim 26 , 514/530 claim 26 , 538/546 ...

Подробнее
24-07-2014 дата публикации

Hydroxamic Acid Derivatives Useful As Antibacterial Agents

Номер: US20140206651A1
Принадлежит: PFIZER INC.

The invention relates to a compound of formula (I): 4. The compound of any one of the , and , or a pharmaceutically acceptable salt thereof , wherein B is phenyl.5. The compound of any one of , and , or a pharmaceutically acceptable salt thereof , wherein B is selected from the group consisting of -pyridyl , -pyridazinyl , -pyrimidinyl , and -pyrazinyl.6. The compound of any one of , and , or a pharmaceutically acceptable salt thereof , wherein Lis absent.7. The compound of any one of , and , or a pharmaceutically acceptable salt thereof , wherein Ris selected from the group consisting of —(C-C)alkyl , -perfluorinated(C-C)alkyl , —O(C-C)alkyl and —(C-C)alkenyl; wherein each of said —(C-C)alkyl , —O(C-C)alkyl , and —(C-C)alkenyl of said Ris optionally substituted with one to three Rgroups.9. The compound of any one of , and , or a pharmaceutically acceptable salt thereof , wherein Land Lare both absent.10. The compound of any one of , and , or a pharmaceutically acceptable salt thereof , wherein m is 1.12. The compound of selected from the group consisting of:(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methylpentanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methylbutanamide;(2S,3R)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methylbutanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-dimethylpentanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methylhexanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methylheptanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2,5-dimethylhexanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methyl-5,5,5-trifluoropentanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-5-ethoxy-N,3-dihydroxy-2-methyl pentanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-3-(1H-imidazol-4-yl)-2-methylpropanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methyl-3-(1-methyl-1H-imidazol-2-yl)propanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)-N,3-dihydroxy-2-methyl-3-phenylpropanamide;(2S,3S)-2-(biphenyl-4-ylmethoxy)- ...

Подробнее
27-05-2021 дата публикации

COMPOUNDS FOR TREATING INFECTIONS

Номер: US20210155578A1
Принадлежит:

The invention relates to hydrazide compounds and their use in medicine, particularly in treating and/or preventing infections caused by a fungus. 2. The compound as defined in claim 1 , wherein Ris NH—NHand/or wherein n is 1 and Y═Y═O.3. The compound as defined in claim 1 , wherein Z is a phenyl group optionally substituted with one or more groups independently selected from the group consisting of Calkyl claim 1 , Calkenyl claim 1 , halogen claim 1 , —SH claim 1 , —OR claim 1 , —SR claim 1 , OH claim 1 , NO claim 1 , C(O)NH—R claim 1 , —C(O)OR claim 1 , —OC(O)R claim 1 , CF claim 1 , CN claim 1 , —NH claim 1 , NHOH claim 1 , —NHNH claim 1 , —NH—CHand —NRRwherein Ris Calkyl claim 1 , aryl or hydrogen claim 1 , wherein Rand Rare independently Calkyl groups claim 1 , aryl groups claim 1 , —C(O)R claim 1 , —OC(O)R claim 1 , or —C(O)OR.5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)12. The method according to wherein Y═Y═O claim 11 , n=0 claim 11 , and Q is a phenyl group optionally substituted in para position with a group selected from the group consisting of H claim 11 , halogen claim 11 , CHand OCH.14Candida, AspergillusSaccharomyces.. The method according to wherein the fungus is from genus or15CandidaC. albicans, C. parapsilopsis, C. tropicalis, C. lusitaniaeC. guilliermondiAspergillusA. fumigatus, A. flavus, A. nigerA. terreusSaccharomycesS. cerevisiae.. The method according to wherein the fungus from genus is claim 14 , or claim 14 , the fungus from genus is or and/or the fungus from is This application is a § 371 national stage of PCT International Application No. PCT/EP2018/070700, filed Jul. 31, 2018, claiming priority of European Patent Application No. 17 382 521.7, filed Jul. 31, 2017, the contents of each of which are hereby incorporated by reference into this application.The present invention relates to new compounds and their use in medicine, particularly as agents able to treat and/or prevent infections caused by fungus. ...

Подробнее
02-05-2019 дата публикации

NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA

Номер: US20190127317A1
Принадлежит:

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin β and/or α, and compounds and pharmaceutical compositions for use in such methods. 3. The compound according to claim 1 , wherein Ris H.4. (canceled)5. The compound according to claim 1 , wherein Ris selected from the group consisting of arylmethyl claim 1 , (alkoxyaryl)methyl claim 1 , (hydroxyaryl)methyl claim 1 , (carboxyaryl)methyl claim 1 , (alkoxyheteroaryl)methyl claim 1 , (heteroarylaryl)methyl claim 1 , (hydroxyheteroaryl)methyl and (carboxyheteroaryl)methyl claim 1 , each of which can be optionally substituted.7. The compound according to claim 1 , wherein Ris selected from the group consisting of (1 claim 1 ,3-benzodioxol-5-yl)methyl claim 1 , (3-carboxyphenyl)methyl claim 1 , and (4-carboxyphenyl)methyl.8. The compound according to claim 1 , wherein Ris selected from the group consisting of aryl claim 1 , alkoxyaryl claim 1 , carboxyaryl claim 1 , cyanoaryl claim 1 , haloaryl claim 1 , hydroxyaryl claim 1 , alkoxyheteroaryl claim 1 , cyanoheteroaryl claim 1 , haloheteroaryl claim 1 , heteroarylaryl claim 1 , hydroxyheteroaryl and carboxyheteroaryl claim 1 , each of which can be optionally substituted.10. The compound according to claim 1 , wherein Ris selected from the group consisting of 1 claim 1 ,3-benzodioxol-5-yl claim 1 , 3-carboxyphenyl claim 1 , 1 claim 1 ,3-benzodioxol-5-yl claim 1 , 3-carboxyphenyl claim 1 , 4-carboxyphenyl claim 1 , 3-carboxy-4-methoxyphenyl claim 1 , 3 claim 1 ,5-dichloro-4-hydroxyphenyl claim 1 , 4-chlorophenyl claim 1 , 4-cyanophenyl claim 1 , 4-fluorophenyl claim 1 , 2 claim 1 ,6-difluoro-4-methoxyphenyl claim 1 , 3-fluoro-4-methoxyphenyl claim 1 , 3-methoxyphenyl claim 1 , 4-methoxyphenyl claim 1 , 4-chlorophenyl claim 1 , and 4-methylphenyl.11. The compound ...

Подробнее
03-06-2021 дата публикации

Photoswitchable HDAC Inhibitors

Номер: US20210162048A1
Принадлежит:

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. 2. The compound of claim 1 , wherein Y is substituted by one or more HDAC targeting elements and X is substituted by one or more fluorescent moieties.4. (canceled)5. The compound of claim 3 , wherein each Ris independently selected from the group consisting of: NRR claim 3 , OR claim 3 , SR claim 3 , Calkyl claim 3 , CH═N—NRR claim 3 , CH═C(NRR) claim 3 , NRCOR claim 3 , NRC(O)NRR claim 3 , aryl claim 3 , and heteroaryl; wherein each R claim 3 , R claim 3 , and Ris independently selected from H and Calkyl.6. The compound of claim 1 , wherein n is 1 and Ris in the para position on the ring.7. (canceled)8. The compound of claim 1 , wherein m is 0 and Ris in the ortho position on the ring.9. The compound of claim 1 , wherein m is 1 and Ris in the ortho position and the Ris in the meta position across the ring from the first R.10. The compound of claim 1 , wherein the HDAC targeting element is selected from the group consisting of: a substituted or unsubstituted aminobenzamide claim 1 , a substituted or unsubstituted hydroxybenzamide claim 1 , and a hydroxamic acid.11. The compound of claim 10 , wherein the HDAC targeting element is selected from the group consisting of: CI-994 claim 10 , Entinostat (MS-275) claim 10 , HDAC1/2 selective CI-994 analog claim 10 , Mocetinostat (MGCD0103) claim 10 , and analogs thereof.15. A method of treating a proliferative disorder in a patient claim 1 , the method comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the patient.16. The method of claim 15 , further comprisingexposing the patient to light suitable to convert the compound, or a pharmaceutically acceptable salt thereof, to its cis confirmation.17. A method of treating cancer in a patient claim 1 , the method comprising administering a therapeutically effective amount of a ...

Подробнее
03-06-2021 дата публикации

COMPOSITIONS AND METHODS FOR TREATING CANCER

Номер: US20210163403A1
Принадлежит: CEDARS-SINAI MEDICAL CENTER

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject. 2. The compound of wherein Y is —CH(NH)CHOH claim 1 , —CHCHNHC(O)CH claim 1 , —CHC(O)NHOH claim 1 , —C(O)CH(NH)CHOH claim 1 , —C(O)CH(NH)CHOH claim 1 , —CH(NH)CHOH claim 1 , —NHC(O)CH(NH)CHOH claim 1 , piperidinecarbxamide claim 1 , piperidone claim 1 , or N-hydroxybenzamide.3. The compound of wherein the compound is represented Formula IA.4. The compound of wherein n is 1.5. The compound of wherein Y is alkyl.6. The compound of wherein Y is —(C-C)alkyl.7. The compound of wherein Y is heteroalkyl.8. The compound of wherein Y is aryl.9. The compound of wherein Y is cyclyl claim 4 , heterocyclyl claim 4 , or heteroaryl.10. The compound of wherein n is 2.11. The compound of wherein Y is —(C-C)alkyl claim 10 , heteroalkyl claim 10 , cyclyl claim 10 , heterocyclyl claim 10 , or heteroaryl.12. The compound of wherein n is 3 and Y is alkyl claim 3 , heteroalkyl claim 3 , cyclyl claim 3 , heterocyclyl claim 3 , or heteroaryl.13. The compound of wherein the compound is represented Formula IB.14. The compound of wherein n is 1.15. The compound of wherein Y is alkyl.16. The compound of wherein Y is heteroalkyl or heteroaryl.17. The compound of wherein Y is cyclyl claim 14 , heterocyclyl claim 14 , or aryl.18. The compound of wherein n is 2.19. The compound of wherein Y is alkyl claim 18 , heteroalkyl claim 18 , heterocyclyl claim 18 , or aryl.20. The compound of wherein Y is cyclyl or heteroaryl.21. The compound of wherein n is 3.23. A method for treating claim 1 , inhibiting claim 1 , or reducing the severity of cancer that overexpress ONECUT2 in a subject in need thereof comprising administering a therapeutically ...

Подробнее
19-05-2016 дата публикации

HDAC INHIBITORS

Номер: US20160137594A1
Принадлежит:

Compounds of formula (I) inhibit HDAC activity: 122-. (canceled)24. The compound or pharmaceutically acceptable salt thereof according to wherein the radical HONHC(═O)—W— is attached to the ring containing A claim 23 , B claim 23 , and D in a position meta- or para- to the radical RRCHNHYLX[CH]—.26. The compound or pharmaceutically acceptable salt thereof according to wherein the radical —YLX[CH]— is —CH—.27. The compound or pharmaceutically acceptable salt thereof according to wherein Ris methyl claim 23 , ethyl claim 23 , n- or iso-propyl claim 23 , n- claim 23 , sec- or tert-butyl claim 23 , cyclohexyl claim 23 , allyl claim 23 , phenyl claim 23 , benzyl claim 23 , 2- claim 23 , 3- or 4-pyridylmethyl claim 23 , N-methylpiperidin-4-yl claim 23 , tetrahydrofuran-3-yl or methoxyethyl.28. The compound or pharmaceutically acceptable salt thereof according to wherein Ris cyclopentyl.29. The compound or pharmaceutically acceptable salt thereof according to wherein Ris phenyl claim 23 , benzyl claim 23 , phenylethyl claim 23 , tert-butoxymethyl or iso-butyl.30. The compound or pharmaceutically acceptable salt thereof according to wherein Ris —CH(CH) claim 23 , cyclohexyl claim 23 , —CHO(t-Bu) claim 23 , —CHS(t-Bu) claim 23 , or phenyl.32. The compound or pharmaceutically acceptable salt thereof according to wherein Ris methyl claim 31 , ethyl claim 31 , n- or iso-propyl claim 31 , n- claim 31 , sec- or tert-butyl claim 31 , cyclohexyl claim 31 , allyl claim 31 , phenyl claim 31 , benzyl claim 31 , 2- claim 31 , 3- or 4-pyridylmethyl claim 31 , N-methylpiperidin-4-yl claim 31 , tetrahydrofuran-3-yl or methoxyethyl.33. The compound or pharmaceutically acceptable salt thereof according to wherein Ris cyclopentyl.34. The compound or pharmaceutically acceptable salt thereof according to wherein Ris phenyl claim 31 , benzyl claim 31 , phenylethyl claim 31 , tert-butoxymethyl or iso-butyl.35. The compound or pharmaceutically acceptable salt thereof according to wherein Ris —CH( ...

Подробнее
17-05-2018 дата публикации

QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES

Номер: US20180133175A1
Принадлежит:

The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases. 129.-. (canceled)31. The compound of claim 30 , wherein R is methyl.32. The compound of claim 30 , wherein R is methoxy.33. The compound of claim 30 , wherein each Ris methyl or ethyl.34. The compound of claim 30 , wherein at least one Ris hydrogen.35. The compound of claim 30 , wherein at least one Ris alkyl.36. The compound of claim 30 , wherein one Ris alkyl claim 30 , and one Ris hydrogen.37. The compound of claim 30 , wherein Y is NROR.38. The compound of claim 30 , wherein Y is N(R).39. The compound of claim 30 , wherein both Rare methyl.40. The compound of claim 30 , wherein Ris C-Calkyl.41. The compound of claim 30 , wherein Ris Calkyl.42. The compound of claim 30 , wherein Ris n-nonyl.43. The compound of claim 30 , wherein Ris C-Calkyl.44. The compound of claim 30 , wherein Ris C-Calkyl.45. The compound of claim 30 , wherein Ris C-Calkyl.46. The compound of claim 30 , wherein Ris methyl.47. A pharmaceutical composition comprising one or more compounds of .48. The composition of claim 47 , further comprising one or more carriers claim 47 , or excipients claim 47 , or a combination thereof.49. A unit dose or unit dosage form composition comprising one or more compounds of for treating a disease responsive to Ape1 inhibition. This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 61/490,141, filed May 26, 2011, which is expressly incorporated by reference herein.The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.Apurinic/apyrimidic ...

Подробнее
08-09-2022 дата публикации

CYCLIC DIONES AS HERBICIDAL COMPOUNDS

Номер: US20220281804A1
Принадлежит: SYNGENTA CROP PROTECTION AG

The present invention relates to compounds of Formula (I), wherein R, R, R, R, R, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling weeds, in particular in crops of useful plants. 2. The compound according to claim 1 , wherein Ris 1-propynyl.3. The compound according to claim 1 , wherein Ris a 5 or 6 membered heteroaryl which comprises one or two nitrogen heteroatoms claim 1 , said phenyl and heteroaryl optionally substituted by one or two Rsubstituents.4. The compound according to claim 1 , wherein Ris methyl.5. The compound according to claim claim 1 , wherein Ris methyl.6. The compound according to claim 1 , wherein Ris R.7. The compound according to claim 1 , wherein Ris R.8. The compound according to claim 1 , wherein G is hydrogen.9. The compound according to claim 1 , wherein G is —C(O)C-Calkyl.10. The compound according to claim 1 , wherein G is —C(O)—O—C-Calkyl.11. A herbicidal composition comprising a compound of Formula (I) according to and an agriculturally acceptable formulation adjuvant.12. The herbicidal composition according to claim 11 , further comprising at least one additional pesticide.13. The herbicidal composition according to claim 12 , wherein the additional pesticide is a herbicide or herbicide safener.14. A method of controlling weeds at a locus comprising application to the locus of a weed controlling amount of a composition according to .15. Use of a compound of Formula (I) as defined in as a herbicide. The present invention relates to novel herbicidal cyclohexanedione compounds, to processes for their preparation, to herbicidal compositions which comprise the novel compounds, and to their use for controlling weeds.Herbicidal cyclic dione compounds substituted by a phenyl which has various substituents are disclosed in, for example, WO2008/110308, WO2014/191534 and WO2015/197468. The present invention relates to novel ...

Подробнее
08-09-2022 дата публикации

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

Номер: US20220281815A1
Принадлежит:

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like. 133-. (canceled)35. The method of claim 34 , wherein the condition is mediated by both LSD1 and HDAC1.36. The method of claim 34 , wherein the condition is mediated by both LSD1 and HDAC6.37. The method of claim 34 , wherein the condition is mediated by HDAC.38. The method of claim 34 , wherein the condition is a proliferative disorder or cancer.39. The method of claim 34 , wherein the condition is cancer.40. The method of claim 39 , wherein the cancer is breast cancer claim 39 , prostate cancer claim 39 , pancreatic cancer claim 39 , gastric cancer claim 39 , lung cancer claim 39 , colon cancer claim 39 , rectal cancer claim 39 , esophagus cancer claim 39 , duodenal cancer claim 39 , tongue cancer claim 39 , pharyngeal cancer claim 39 , brain tumor claim 39 , neurinoma claim 39 , non-small cell lung cancer claim 39 , small cell lung cancer claim 39 , liver cancer claim 39 , kidney cancer claim 39 , bile duct cancer claim 39 , uterine body cancer claim 39 , cervical cancer claim 39 , ovarian cancer claim 39 , urinary & bladder cancer claim 39 , skin cancer claim 39 , hemangioma claim 39 , malignant lymphoma claim 39 , malignant melanoma claim 39 , thyroid cancer claim 39 , bone tumor claim 39 , vascular fibroma claim 39 , retinoblastoma claim 39 , penile cancer claim 39 , pediatric solid cancer claim 39 , Myelodysplastic syndrome (MDS) claim 39 , lymphoma claim 39 , myeloma claim 39 , leukemia claim 39 , acute myelogenous leukemia (AML) claim 39 , chronic myelogenous leukemia ...

Подробнее
28-05-2015 дата публикации

3,5,N-TRIHYDROXY-ALKANAMIDE AND DERIVATIVES: METHOD FOR MAKING SAME AND USE THEREOF

Номер: US20150148360A1
Принадлежит:

The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells. 14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.15. A method for treating cancer; hypercholesterolemia claim 1 , an acute or chronic inflammatory disease claim 1 , autoimmune disease claim 1 , allergic diseases claim 1 , pathogen infection claim 1 , neurodegenerative disease claim 1 , or disease associated with oxidative stress claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of .'}16. The method of claim 15 , wherein the subject is a human subject having claim 15 , suspected of having claim 15 , or at risk for the cancer.17. The method of claim 15 , wherein the cancer is selected from the group consisting of leukemia claim 15 , Hodgkin's disease claim 15 , lymphoma claim 15 , Ewing's sarcoma claim 15 , multiple myeloma claim 15 , Wilms' tumor claim 15 , bone tumor claim 15 , neuroblastoma claim 15 , retinoblastoma claim 15 , testicular cancer claim 15 , thyroid cancer claim 15 , prostate cancer claim 15 , larynx cancer claim 15 , cervical cancer claim 15 , nasopharynx cancer claim 15 , breast cancer claim 15 , colon cancer claim 15 , pancreatic ...

Подробнее
24-05-2018 дата публикации

COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS

Номер: US20180141891A1
Автор: Phares Ken
Принадлежит: United Therapeutics Corporation

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. 1. A method of treating pulmonary hypertension , treating peripheral vascular disease , promoting vasodilation , inhibiting platelet aggregation and thrombus formation , stimulating thrombolysis , inhibiting cell proliferation , providing cytoprotection , preventing atherogenesis , or inducing angiogenesis comprising administering to a patient in need thereof a pharmaceutically effective amount of a prodrug of treprostinil , wherein the prodrug converts to treprostinil upon said administration.2. The method of claim 1 , wherein the prodrug has no activity before being converted to treprostinil.3. The method of claim 1 , wherein the prodrug is administered by oral administration.4. The method of claim 1 , wherein the prodrug is administered by ingestion.5. The method of claim 1 , wherein the prodrug is administered by transmucosal administration.6. The method of claim 1 , wherein the prodrug is administered by parenteral administration.7. The method of claim 1 , wherein the prodrug is administered by subcutaneous administration.8. The method of claim 1 , wherein the prodrug is administered by injection.9. The method of claim 8 , wherein the injection is a bolus injection.10. The method of claim 8 , wherein the injection is continuous infusion.11. The method of claim 8 , wherein the injection is an intravenous injection.12. The method of claim 1 , wherein the prodrug is administered by duodenal administration.13. The method of claim 1 , which is a method of treating pulmonary hypertension.14. The method of claim 1 , wherein the prodrug is an ester of treprostinil.15. The method of claim 14 , which is a method of treating pulmonary ...

Подробнее
24-05-2018 дата публикации

AUTOTAXIN INHIBITORS AND USES THEREOF

Номер: US20180141965A1
Автор: Kokotos George

Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases). 5. A composition comprising a compound according to and a pharmaceutically acceptable carrier or excipient.6. A compound according to for use as a medicament.7. A compound according to for use in inhibiting autotaxin (ATX) activity in a biological system.8. A compound according to for use in the prevention or treatment of an inflammatory disease or condition in a subject.9. A compound according to for use in the prevention or treatment of cancer in a subject.10. A compound according to for use in the prevention or treatment of obesity in a subject.11. A compound according to for use in the prevention or treatment of autoimmune diseases in a subject. Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance. Also described are their uses, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases).Autotaxin (ATX) (also known as ectonucleotide pyrophosphatase/phosphodiesterase 2, Enpp2 or NPP2) is a member of the nucleotide pyrophosphatase/phosphodiesterase family of ectoenzymes, that hydrolyze phosphodiester bonds of various nucleotides and nucleotide derivatives. ATX is a secreted enzyme that possesses lysophopho-lipase D activity and catalyzes the hydrolysis of lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and choline.The product of this enzymatic activity, LPA, is a bioactive lipid mediator that binds to specific G-protein-coupled receptors (LPAin mammals) and activates various signal transduction pathways including the migration, proliferation, ...

Подробнее
02-06-2016 дата публикации

PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

Номер: US20160152570A1
Принадлежит:

The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders. 2. The compound of claim 1 , wherein Ris —H or —Calkyl.3. The compound of claim 2 , wherein Ris —H claim 2 , methyl claim 2 , ethyl claim 2 , propyl claim 2 , or isopropyl.4. The compound of claim 1 , wherein Ris —H claim 1 , —Calkyl claim 1 , aryl claim 1 , 5-10 membered heteroaryl claim 1 , —Ccycloaliphatic claim 1 , or 3-8 membered heterocycloaliphatic claim 1 , each of which is optionally substituted with 1-3 groups selected from halo claim 1 , —OH claim 1 , or phenyl.5. The compound of claim 4 , wherein Ris —H or —Calkyl.6. The compound of claim 5 , wherein Ris —H claim 5 , methyl claim 5 , ethyl claim 5 , propyl claim 5 , or isopropyl.7. The compound of claim 1 , wherein Rand Rtogether with the atoms to which they are attached form an optionally substituted 5-8 membered saturated or partially unsaturated heterocyclic ring that includes an N atom claim 1 , an O atom claim 1 , and up to 1 additional heteroatom selected from N claim 1 , O claim 1 , or S.8. The compound of claim 1 , wherein Ris —Calkyl optionally substituted with 1-3 groups selected from halo claim 1 , —OH claim 1 , or phenyl.9. The compound of claim 8 , wherein Ris methyl or ethyl.10. The compound of claim 1 , wherein n is 1.11. The compound of claim 10 , wherein one of Rand Ris H and the other is independently selected from —H or —OH claim 10 , or Rand Rtogether form oxo.12. The compound of claim 1 , wherein one of n is 0.13. The compound of claim 12 , wherein both of Rand Rare —H.14. The compound of claim 1 , wherein ring A is a 6-membered ...

Подробнее
15-09-2022 дата публикации

COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS

Номер: US20220289660A1
Автор: Phares Ken
Принадлежит: United Therapeutics Corporation

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing 112.-. (canceled)13. A pharmaceutical composition comprising a) an effective amount of treprostinil or a pharmaceutically acceptable salt or ester thereof and b) polysorbate 80.14. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is in the form of a powder.15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition further comprises a buffer.16. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition further comprises a buffer.17. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition comprises a) a pharmaceutically acceptable salt of treprostinil and b) polysorbate 80.18. The pharmaceutical composition of claim 17 , wherein the pharmaceutically acceptable salt is treprostinil sodium.19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is in the form of a powder.20. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is in the form of a powder.21. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition further comprises a buffer.22. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition further comprises a buffer.23. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition further comprises a buffer.24. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition further comprises a buffer. This application is a continuation of U.S. application Ser. No. 16/784,720, filed Feb. 7, 2020, which is a continuation of U.S. application Ser. No. 16/519,491, filed Jul. ...

Подробнее
15-09-2022 дата публикации

N-FORMYLHYDROXYLAMINES AS NEPRILYSIN (NEP) INHIBITORS, IN PARTICULAR AS MIXED AMINOPEPTIDASE N (APN) AND NEPRILYSIN (NEP) INHIBITORS

Номер: US20220289668A1
Принадлежит:

The present invention relates to a compound of following formula (I): 1. A compound of following formula (I):{'br': None, 'sub': 2', '1', '2', 'n', '2', '2', 'm', '3, 'H—CO—N(OH)—CH—CH(R)—CO—NH—(CH)—CH(R)—(CH)—CO—R\u2003\u2003(I)'}wherein:{'sub': '1', 'claim-text': [{'sub': 4', '4, 'an aryl, itself non-substituted or substituted by one or more groups selected from halogens, a phenyl group, a benzyl group, an ORgroup, Rbeing selected from hydrogen and a linear or branched alkyl group comprising from 1 to 4 carbon atoms, and combinations thereof,'}, 'a 5 or 6 membered heteroaryl comprising 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulphur, and', 'a 5 or 6 membered cycloheteroalkyl comprising 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulphur,, 'Rrepresents a linear or branched hydrocarbon group comprising from 1 to 6 carbon atoms substituted by one or more groups selected from{'sub': '2', 'claim-text': a linear or branched hydrocarbon group comprising from 1 to 6 carbon atoms, non-substituted or substituted by one or more groups selected from:', {'sub': 5', '5', '5', '5, 'a group selected from OR, SRand S(O)R, Rbeing selected from hydrogen and a linear or branched alkyl group comprising from 1 to 4 carbon atoms,'}, {'sub': 2', '6', '6, 'a CORgroup, Rbeing selected from hydrogen, a linear or branched alkyl group comprising from 2 to 4 carbon atoms and a benzyl group,'}, {'sub': 5', '5, 'an aryl, itself non-substituted or substituted by one or more groups selected from halogens, an ORgroup, Rhaving the same definition as above, and combinations thereof,'}, 'a 5 or 6 membered heteroaryl comprising 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulphur,', 'a 5 or 6 membered cycloalkyl, and', 'a 5 or 6 membered cycloheteroalkyl comprising 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulphur,', {'sub': 5', '5, 'an aryl, non-substituted or ...

Подробнее
09-06-2016 дата публикации

REACTION ACCELERATOR AND METHOD OF PRODUCING URETHANE COMPOUND, THIOURETHANE COMPOUND, AMIDE COMPOUND, OR UREA COMPOUND USING SAME

Номер: US20160159733A1
Принадлежит: SHOWA DENKO K.K.

A reaction accelerator is provided which is used in a reaction of a compound including an isocyanate group that is not directly bonded to an aromatic ring in a molecule with a compound including an active hydrogen-containing group and is formed of a compound including a halogenated carbamoyl group. A production method is provided which includes reacting a compound including an isocyanate group that is not directly bonded to an aromatic ring in a molecule with a compound including an active hydrogen-containing group to produce a urethane compound, a thiourethane compound, an amide compound or a urea compound, in which the reaction is performed in the presence of the reaction accelerator. 1. A reaction accelerator , whereinthe reaction accelerator is used in a reaction of a compound comprising an isocyanate group in a molecule, in which the isocyanate group is not directly bonded to an aromatic ring, with a compound including an active hydrogen-containing group, andthe reaction accelerator is a compound including a halogenated carbamoyl group.2. The reaction accelerator according to claim 1 , wherein the reaction is a reaction that generates a urethane compound claim 1 , a thiourethane compound claim 1 , an amide compound or a urea compound.3. The reaction accelerator according to claim 1 , wherein the compound comprising an isocyanate group that is not directly bonded to an aromatic ring in a molecule is at least one selected from a group consisting of hexamethylene diisocyanate claim 1 , trimethyl hexamethylene diisocyanate claim 1 , lysine diisocyanate claim 1 , norbornane diisocyanate claim 1 , trans-cyclohexane-1 claim 1 ,4-diisocyanate claim 1 , isophorone diisocyanate claim 1 , bis(isocyanate methyl)cyclohexane claim 1 , dicyclohexylmethane diisocyanate claim 1 , dimer acid diisocyanate claim 1 , m-xylene diisocyanate claim 1 , m-tetramethylxylene diisocyanate claim 1 , other diisocyanate compounds represented by the general formula OCN—R—NCO (R represents a ...

Подробнее
08-06-2017 дата публикации

Small molecule compound and synthesizing method and uses thereof

Номер: US20170158651A1
Принадлежит: Technoderma Medicines Pte Ltd

Provided is a small molecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth of the hairs, thus exhibiting an obvious effect of promoting hair growth. In addition, changes in the weight of a mouse in each group are slow, indicating that the test compound does not cause weight loss in an animal.

Подробнее
08-06-2017 дата публикации

PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO

Номер: US20170158674A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses molecules having the following formula (“Formula One”): 2. A molecule according to wherein R2 and R4 are selected from F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , CN claim 1 , and NOand R1 claim 1 , R3 claim 1 , and R5 are H.3. A molecule according to wherein R2 claim 1 , R3 claim 1 , and R4 are selected from F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , CN claim 1 , and NOand R1 claim 1 , and R5 are H.4. A molecule according to wherein R2 claim 1 , R3 claim 1 , and R4 are independently selected from F and Cl and R1 and R5 are H.5. A molecule according to wherein R1 is selected from Cl and H.6. A molecule according to wherein R2 is selected from CF claim 1 , CH claim 1 , Cl claim 1 , F claim 1 , and H.7. A molecule according to wherein R3 is selected from OCH claim 1 , CH claim 1 , F claim 1 , Cl claim 1 , or H.8. A molecule according to wherein R4 is selected from CF claim 1 , CH claim 1 , Cl claim 1 , F claim 1 , and H.9. A molecule according to wherein R5 is selected from F claim 1 , Cl claim 1 , and H.10. A molecule according to wherein R6 is trifluoromethyl.11. A molecule according to wherein R7 is selected from H claim 1 , F claim 1 , Cl claim 1 , Br claim 1 , and I.12. A molecule according to wherein R7 is selected from H claim 1 , OCH claim 1 , and OH.13. A molecule according to wherein R8 is selected from CHand H.14. A molecule according to wherein R10 is selected from Cl claim 1 , Br claim 1 , CH claim 1 , and CF.15. A composition comprising a molecule according to and further comprising:(a) one or more compounds having acaricidal, algicidal, avicidal, bactericidal, fungicidal, herbicidal, insecticidal, molluscicidal, nematicidal, rodenticidal, or virucidal properties; or(b) one or more compounds that are antifeedants, bird repellents, chemosterilants, herbicide safeners, insect attractants, insect repellents, mammal repellents, mating disrupters, plant activators, plant growth regulators, or synergists; or(c) both (a) and ...

Подробнее
08-06-2017 дата публикации

PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO

Номер: US20170158675A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses molecules having the following formula (“Formula One”): 2. A composition according to further comprising:(a) one or more compounds having acaricidal, algicidal, avicidal, bactericidal, fungicidal, herbicidal, insecticidal, molluscicidal, nematicidal, rodenticidal, or virucidal properties; or(b) one or more compounds that are antifeedants, bird repellents, chemosterilants, herbicide safeners, insect attractants, insect repellents, mammal repellents, mating disrupters, plant activators, plant growth regulators, or synergists; or(c) both (a) and (b).3. A composition according to wherein further comprising one or more compounds selected from: (3-ethoxypropyl)mercury bromide claim 1 , 1 claim 1 ,2-dichloropropane claim 1 , 1 claim 1 ,3-dichloropropene claim 1 , 1-methylcyclopropene claim 1 , 1-naphthol claim 1 , 2-(octylthio)ethanol claim 1 , 2 claim 1 ,3 claim 1 ,5-tri-iodobenzoic acid claim 1 , 2 claim 1 ,3 claim 1 ,6-TBA claim 1 , 2 claim 1 ,3 claim 1 ,6-TBA-dimethylammonium claim 1 , 2 claim 1 ,3 claim 1 ,6-TBA-lithium claim 1 , 2 claim 1 ,3 claim 1 ,6-TBA-potassium claim 1 , 2 claim 1 ,3 claim 1 ,6-TBA-sodium claim 1 , 2 claim 1 ,4 claim 1 ,5-T claim 1 , 2 claim 1 ,4 claim 1 ,5-T-2-butoxypropyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-2-ethylhexyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-3-butoxypropyl claim 1 , 2 claim 1 ,4 claim 1 ,5-TB claim 1 , 2 claim 1 ,4 claim 1 ,5-T-butometyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-butotyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-butyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-isobutyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-isoctyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-isopropyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-methyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-pentyl claim 1 , 2 claim 1 ,4 claim 1 ,5-T-sodium claim 1 , 2 claim 1 ,4 claim 1 ,5-T-triethylammonium claim 1 , 2 claim 1 ,4 claim 1 ,5-T-trolamine claim 1 , 2 claim 1 ,4-D claim 1 , 2 claim 1 ,4-D-2-butoxypropyl claim 1 , 2 claim 1 ,4-D-2-ethylhexyl claim 1 , 2 claim 1 ,4-D-3- ...

Подробнее
18-06-2015 дата публикации

Neprilysin inhibitors

Номер: US20150166469A1
Принадлежит: Theravance Biopharma R&D Ip Llc

In one aspect, the invention relates to compounds having the formula: where R 1 -R 5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Подробнее
28-08-2014 дата публикации

SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF

Номер: US20140243334A1
Принадлежит: Millennium Pharmaceuticals, Inc.

This invention provides compounds of formula (I): 2. The compound of claim 1 , wherein G is —R claim 1 , —V—R claim 1 , —V-L-R claim 1 , -L-V—R claim 1 , or -L-R.3. The compound of claim 2 , wherein:{'sup': 2a', '1, 'Ris R;'}{'sup': '2b', 'Ris G;'}{'sup': 2c', '1, 'Ris R; and'}{'sup': '2d', 'sub': '1', 'Ris R.'}4. The compound of claim 2 , wherein:{'sup': 2a', '1, 'Ris R;'}{'sup': 2b', '1, 'Ris R;'}{'sup': '2c', 'Ris G; and'}{'sup': 2d', '1, 'Ris R.'}5. The compound of claim 2 , wherein:{'sub': 1', '1, 'sup': 3', '3', '3, 'G is —V—R, -L-R, or —R;'}{'sub': 1', '2', '2', '2, 'Lis —CH— or —CHCH—; and'}{'sub': 1', '2, 'sup': 4a', '4a', '4a', '4a', '4a', '4a', '4a, 'Vis —N(R)—, —N(R)—C(O)—, —C(O)—N(R)—, —N(R)—SO—, —O—, —N(R)—C(O)—O—, or —N(R)—C(O)—N(R)—.'}6. The compound of claim 2 , wherein:{'sup': '1a', 'each occurrence of Ris independently hydrogen, fluoro, trifluoromethyl, or methyl;'}{'sup': '1b', 'each occurrence of Ris hydrogen;'}{'sup': '1c', 'Ris hydrogen, hydroxy, fluoro, trifluoromethyl, or methyl;'}{'sup': '1', 'each occurrence of Ris independently hydrogen, chloro, fluoro, cyano, hydroxy, methoxy, ethoxy, trifluoromethyl, methyl, or ethyl.'}7. The compound of claim 2 , wherein:{'sup': 3', '5dd, 'each substitutable carbon chain atom in Ris unsubstituted or substituted with 1-2 occurrences of R;'}{'sup': 3', '5', '5aa, 'sub': '2', 'each substitutable saturated ring carbon atom in Ris unsubstituted or substituted with ═O, ═C(R), or —R;'}{'sup': 3', '5a, 'each substitutable unsaturated ring carbon atom in Ris unsubstituted or is substituted with —R;'}{'sup': 3', '9b, 'claim-text': [{'sup': 5a', '5', '5', '5', '5', '6', '6', '6', '4', '4', '4', '6', '4', '4', '4', '6', '4', '6', '4', '4', '6', '4', '4', '5a, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '1-6, 'each Ris independently halogen, —NO, —CN, —C(R)═C(R), —C≡C—R, —OR, —SR, —S(O)R, —SOR, —SON(R), —N(R), —NRC(O)R, —NRC(O)N(R), —NRCOR, —OC(O)N(R), —C(O)R, —C(O)N(R), —N(R)SOR, —N(R) ...

Подробнее
16-06-2016 дата публикации

NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF

Номер: US20160168084A1
Принадлежит:

Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof. 2. Compound of formula (I′) according to claim 1 , wherein Ar is chosen fromi) a phenyl substituted at the meta-, para- or ortho-position by a fluor or a thiazolyl, orii) a benzyl substituted at the meta-position by an C1 to C4 alkoxy group.9. A method for treating claim 1 , inhibiting or preventing a parasitic disease in a mammalian subject claim 1 , including human claim 1 , cat or dog claim 1 , comprising applying an effective amount of the compound of formula (I′) of in the form of a pharmaceutical drug.10TrypanosomaLeishmaniaToxoplasma gondii.. The method of claim 9 , wherein the parasitic disease is caused by a protozoan parasite of the family of the Trypanosomatidae selected from the genus or the genus claim 9 , or the parasite11. A method for treating toxoplasmosis claim 4 , comprising applying an effective amount of the compound of formula (Ia1) of in the form of a pharmaceutical drug.12. A pharmaceutical composition comprising a compound of formula (I′) according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutical acceptable excipient.13. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a compound of formula (I′) according , or a pharmaceutically acceptable salt thereof, and'}at least one anti-parasitic compound, selected from the group comprising: miltefosin, antimony based drugs, like meglumine antimoniate or sodium stibogluconate, amphotericin B, benzimidazol, nifurtimox, paromomycin, pentamidin and its derivatives, arsenic derivatives, melarsoprol and difluoromethylornithin.16. The compound of claim 1 , wherein Ar is a phenyl.17. The compound of claim 1 , wherein Ar is a benzyl.18. The compound of claim 1 , wherein the halogen is a fluor atom.19. The compound of claim 1 , wherein the halogen is a thiazolyl.20. the ...

Подробнее
15-06-2017 дата публикации

Process for Preparing N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic Acid Ethyl Ester

Номер: US20170166517A1
Принадлежит: NOVARTIS AG

This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I below and other intermediates that are used in such processes.

Подробнее
01-07-2021 дата публикации

Novel inhibitors of meprin alpha and beta

Номер: US20210198189A1
Принадлежит: Vivoryon Therapeutics AG

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin β and/or α, and compounds and pharmaceutical compositions for use in such methods.

Подробнее
21-06-2018 дата публикации

PPAR AGONISTS

Номер: US20180170857A1
Принадлежит:

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases). 3. The compound of claim 1 , wherein ring B is selected from phenyl claim 1 , pyridine claim 1 , thiophene claim 1 , thiazole claim 1 , pyrazole claim 1 , oxazole claim 1 , isoxazole claim 1 , benzo[b]furan claim 1 , indazole claim 1 , piperidine claim 1 , cyclohexane claim 1 , piperidin-2-one claim 1 , piperazine-2 claim 1 ,5-dione or quinazolin-4(3H)-one.6. The compound of claim 1 , wherein Ris selected from alkyl claim 1 , heteroalkyl claim 1 , cycloalkyl claim 1 , heterocycloalkyl claim 1 , aryl or heteroaryl.7. The method of claim 1 , wherein L claim 1 , Land Lare each independently selected from a bond or alkylene.8. The compound of claim 1 , wherein LRis isopropyl claim 1 , cyclopropyl claim 1 , cyclopentyl claim 1 , sec-butyl claim 1 , benzyl claim 1 , morpholinopropyl claim 1 , or (2-pyridinyl)ethyl.9. The compound of claim 1 , wherein each Rindependently is Cl claim 1 , F claim 1 , I claim 1 , Br claim 1 , cyano claim 1 , NO claim 1 , or OH.10. The compound of claim 1 , wherein each Rindependently is halogen claim 1 , alkyloxy claim 1 , haloalkyloxy claim 1 , cycloalkyloxy claim 1 , haloalkyl claim 1 , alkyl claim 1 , amino claim 1 , heterocyclic claim 1 , aryl claim 1 , cycloaliphatic or heteroaryl.11. The compound of claim 1 , wherein n is from 2 to 4 claim 1 , and two adjacent Rgroups form a fused ring system with ring B.13. The compound of claim 1 , wherein n is 1 and Ris furan-2-yl or furan-3-yl.15. The compound of claim 1 , wherein Lis Clinear or branched alkylene.16. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of .17. A method claim 1 , comprising contacting a PPARδ protein with an effective amount of one or more compounds of ...

Подробнее
06-06-2019 дата публикации

Benzoylglycine Derivatives and Methods of Making and Using Same

Номер: US20190169114A1
Принадлежит:

Disclosed are compounds of formulae: 1. A compound which is4-(cyclopropylbuta-1,3-diyn-1-yl)-N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide;N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide;4-((2-(aminomethyl)cyclopropyl)buta-1,3-diyn-1-yl)-N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide;N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-(methylsulfonamidomethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide;N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-(methoxymethyl)cyclopropyl)buta-1,3-diyn-1l-yl)benzamide;N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-((methylamino)methyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide;N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-(2-oxopropyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide;4-((2-(2-amino-2-oxoethyl)cyclopropyl)buta-1,3-diyn-1-yl)-N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide;4-((2-carbamoylcyclopropyl)buta-1,3-diyn-1-yl)-N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide;4-((2-acetylcyclopropyl)buta-1,3-diyn-1-yl)-N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide;or a pharmaceutically acceptable salt thereof.2. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier claim 1 , solvent claim 1 , adjuvant or diluent.3. A method of treating Gram-negative bacterial infections claim 1 , the method comprising administering to a subject in need of such treatment an effective amount of a compound according to .4Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, Alcaligenes xylosoxidans, Acinetobacter, Enterobacteriaceae, Haemophilus, NeisseriaFrancisella ...

Подробнее
02-07-2015 дата публикации

METHOD OF PRODUCING BERAPROST

Номер: US20150183757A1
Принадлежит: LUNG BIOTECHNOLOGY INC.

An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. 16-. (canceled)8. The process of claim 7 , wherein Rand Reach independently represent trimethylsilyl claim 7 , triethylsilyl claim 7 , t-butyldimethylsilyl claim 7 , t-butyldiphenylsilyl claim 7 , phenyldimethylsilyl claim 7 , or tetrahydropyranyl.9. The process of claim 7 , wherein the cycloaddition of step (1) is an inverse electron demand Diels Alder reaction followed by thermal decarboxylation.10. The process of claim 7 , wherein the aromatization step (2) is treatment of the compound of formula (IV) with palladium on carbon.12. The process of claim 11 , wherein the compound of formula (VII) is produced as a substantially pure single isomer.14. The compound of claim 13 , wherein Rand Rare each CH.1520-. (canceled) This application claims priority from U.S. Provisional Application No. 61/497,754, filed Jun. 16, 2011, the entirety of which is incorporated herein by reference.The present application relates to a process for selectively producing single-isomer benzoprostacyclin derivatives including beraprost and its derivatives.The present invention also relates to a novel process for attaching the alpha side-chain to single-isomer key intermediate leading to beraprost and related derivatives.Prostacyclin derivatives are useful pharmaceutical compounds possessing activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and bronchodilation. Beraprost is a synthetic benzoprostacyclin analogue of natural prostacyclin that is currently under clinical trials for the treatment of pulmonary hypertension and vascular disease (excluding renal disease) in North America and Europe.Beraprost and related benzoprostacyclin ...

Подробнее
08-07-2021 дата публикации

Benzoylglycine Derivatives and Methods of Making and Using Same

Номер: US20210206715A1
Принадлежит:

Disclosed are compounds of formulae: 3. The method of claim 1 , wherein Ris —CO(C-Calkyl) claim 1 , —C-Calkyl-CO(C-Calkyl) claim 1 , —C-Calkyl-COH claim 1 , C-Ccycloalkyl optionally substituted with R claim 1 , or (C-Ccycloalkyl)C-Calkyl- optionally substituted with R.4. The method of claim 1 , wherein Ris C-Ccycloalkyl optionally substituted with R; or Ris cyclopropyl claim 1 , cyclopentyl claim 1 , or cyclohexyl claim 1 , each optionally substituted with R.5. The method of claim 1 , wherein each Ris independently selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , —NH claim 1 , —NH(C-Calkyl) claim 1 , —N(C-Calkyl) claim 1 , —OH claim 1 , C-Calkoxy claim 1 , C-Chaloalkoxy claim 1 , —C-Calkyl-OH claim 1 , —C-Calkyl-(C-Calkoxy) claim 1 , —C-Calkyl-NH claim 1 , —C-Calkyl-NH—C-Calkyl) claim 1 , —C-Calkyl-N(C-Calkyl) claim 1 , —C-Calkyl-NH(SOC-Calkyl) claim 1 , —CONH claim 1 , —CON(C-Calkyl) claim 1 , —CON(C-Calkyl) claim 1 , —CO(C-Calkyl) claim 1 , —COH claim 1 , —CO(C-Calkyl) claim 1 , —C-Calkyl-CONH claim 1 , —C-Calkyl-CON(C-Calkyl) claim 1 , —C-Calkyl-CON(C-Calkyl) claim 1 , —C-Calkyl-CO(C-Calkyl) claim 1 , —C-Calkyl-COH claim 1 , and —C-Calkyl-CO(C-Calkyl).6. The method of claim 1 , wherein Ris C-Calkyl claim 1 , C-Chaloalkyl claim 1 , —CO(C-Calkyl) claim 1 , —C-Calkyl-CO(C-Calkyl) claim 1 , —C-Calkyl-COH claim 1 , C-Ccycloalkyl optionally substituted with R claim 1 , or heterocyclyl optionally substituted with R.7. The method of claim 1 , wherein Ris C-Ccycloalkyl optionally substituted with Ror (C-Ccycloalkyl)C-Calkyl- optionally substituted with R; or Ris C-Ccycloalkyl optionally substituted with R; or Ris cyclopropyl claim 1 , cyclopentyl claim 1 , or cyclohexyl claim 1 , each optionally substituted with R.8. The method of claim 1 , wherein each Ris independently selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , —NH claim 1 , —NH(C-Calkyl) claim 1 , —N(C-Calkyl) claim ...

Подробнее
30-06-2016 дата публикации

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

Номер: US20160185737A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. 150-. (canceled)52. The compound of claim 51 , wherein at least one Ris H.53. The compound of claim 51 , wherein X is N.54. The compound of claim 51 , wherein X is O claim 51 , S claim 51 , or P.55. The compound of claim 51 , wherein:X is N;{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, arylalkyl, and alkylarylalkyl;'}{'sup': 2', '3, 'Rand Rare each independently selected from the group consisting of hydrogen, alkyl, alkylaryl, aryl, arylalkyl, alkylarylalkyl, and heterocyclylalkyl;'}{'sup': '4', 'Ris selected from the group consisting of alkyl, alkylaryl, aryl, arylalkyl, and alkylarylalkyl,'}{'sup': 1', '2', '3', '4', '19', '20', '19', '20', '21', '22', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24', '24, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2, 'wherein each R, R, R, and Ris independently unsubstituted or substituted with one or more of the following: alkyl, alkenyl, cycloalkyl, alkylaryl, alkylcarbonyl, aryl, arylalkyl, alkylarylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, —NRR, —SH, ...

Подробнее
13-06-2019 дата публикации

Pharmaceutical Formulation for Histone Deacetylase Inhibitors

Номер: US20190175539A1
Принадлежит:

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula 2. The method of wherein the proliferative disorder is selected from cutaneous T cell lymphoma claim 1 , and a skin cancer.3. The method of wherein the proliferative disorder is selected from cutaneous T-cell lymphoma claim 1 , and claim 1 , basal cell carcinoma.4. The method of claim 3 , wherein the at least one acidifying agent of the pharmaceutical composition is selected from the group consisting of acetic acid claim 3 , dehydro acetic acid claim 3 , ascorbic acid claim 3 , benzoic acid claim 3 , boric acid claim 3 , citric acid claim 3 , edetic acid claim 3 , hydrochloric acid claim 3 , isostearic acid claim 3 , stearic acid claim 3 , lactic acid claim 3 , nitric acid claim 3 , oleic acid claim 3 , phosphoric acid claim 3 , sorbic acid claim 3 , sulfuric acid claim 3 , tartaric acid claim 3 , and undecylenic acid.5. The method of wherein the at least one acidifying agent of the pharmaceutical composition is selected from citric acid claim 4 , acetic acid claim 4 , and phosphoric acid.6. The method of wherein the pharmaceutical composition further comprises at least one humectant.7. The method of claim 6 , wherein the at least one humectant is selected from the group consisting of hexylene glycol claim 6 , glycerin claim 6 , propylene glycol claim 6 , sorbitol claim 6 , lactic acid claim 6 , sodium lactate claim 6 , mannitol claim 6 , butylene glycol claim 6 , panthenol claim 6 , hyaluronic acid claim 6 , urea claim 6 , chitosan claim 6 , polyols claim 6 , methyl gluceth-10 claim 6 , methyl gluceth-20 claim 6 , and polyethylene glycols.8. The method of claim 6 , wherein the at least one humectant is selected from glycerin and hexylene glycol.9. The method of wherein the pharmaceutical composition further comprises at least one emollient.10. The method of wherein the at least one ...

Подробнее
09-07-2015 дата публикации

Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival

Номер: US20150190411A1

The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+−)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.

Подробнее
18-09-2014 дата публикации

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

Номер: US20140275093A1
Принадлежит: Millennium Pharmaceuticals, Inc.

This invention provides compounds of formula (I): 2. The compound of claim 1 , wherein:{'sub': '1', 'sup': '1', 'Xis CR; and'}{'sub': 2', '3, 'sup': '1', '(i) when ring A is connected through position (a), Xis C; and Xis CR; or'}{'sub': 3', '2, 'sup': '1', '(ii) when ring A is connected through position (b), Xis C; and Xis CR.'}3. The compound of claim 1 , wherein:{'sup': '4b', 'Ris H; and'}{'sup': '2', 'Ris methyl, ethyl, isopropyl, n-propyl, trifluoromethyl, tert-butyl, cyclopropyl, or phenyl.'}4. The compound of claim 1 , wherein:{'sub': '1', 'sup': '3', 'G is -V—R; and'}{'sub': 1', '2, 'sup': '4a', 'Vis —C(O)—, —C(O)—N(R)—, or —S(O)—.'}5. The compound of claim 1 , wherein:{'sup': '1', 'Ris hydrogen, chloro, fluoro, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyano, trifluoromethyl, methyl, ethyl, isopropyl, n-propyl, or tert-butyl; and'}{'sup': '10', 'Ris hydrogen.'}7. The compound of claim 6 , wherein:{'sub': '1', 'sup': '1', 'Xis CR; and'}{'sub': 2', '3, 'sup': '1', '(i) when ring A is connected through position (a), Xis C; and Xis CR; or'}{'sub': 3', '2, 'sup': '1', '(ii) when ring A is connected through position (b), Xis C; and Xis CR.'}8. The compound of claim 6 , wherein:{'sup': '4b', 'Ris H; and'}{'sup': '2', 'Ris methyl, ethyl, isopropyl, n-propyl, trifluoromethyl, tert-butyl, cyclopropyl, or phenyl.'}9. The compound of claim 6 , wherein:{'sub': '1', 'sup': '3', 'G is -V—R; and'}{'sub': 1', '2, 'sup': '4a', 'Vis —C(O)—, —C(O)—N(R)—, or —S(O)—.'}10. The compound of claim 6 , wherein:{'sup': '1', 'Ris hydrogen, chloro, fluoro, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyano, trifluoromethyl, methyl, ethyl, isopropyl, n-propyl, or tert-butyl; and'}{'sup': '10', 'Ris hydrogen.'}11. The compound of claim 6 , wherein:{'sup': 3', '5dd, 'each substitutable carbon chain atom in Ris unsubstituted or substituted with 1-2 occurrences of —R;'}{'sup': 3', '5', '4', '5', '5', '6', '6', '5', '5a, 'sub': 2', '2', '2', '2, 'each substitutable saturated ring ...

Подробнее
18-09-2014 дата публикации

METHOD OF PRODUCING BERAPROST

Номер: US20140275573A1
Принадлежит: LUNG BIOTECHNOLOGY INC.

An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. 16.-. (canceled)8. The process of claim 7 , wherein Rand Reach independently represent trimethylsilyl claim 7 , triethylsilyl claim 7 , t-butyldimethylsilyl claim 7 , t-butyldiphenylsilyl claim 7 , phenyldimethylsilyl claim 7 , or tetrahydropyranyl.9. The process of claim 7 , wherein the cycloaddition of step (1) is an inverse electron demand Diels Alder reaction followed by thermal decarboxylation.10. The process of claim 7 , wherein the aromatization step (2) is treatment of the compound of formula (IV) with palladium on carbon.12. The process of claim 11 , wherein the compound of formula (VII) is produced as a substantially pure single isomer.14. The compound of claim 13 , wherein Rand Rare each CH.16. The method of claim 15 , wherein selective reduction of the carbonyl includes an asymmetric catalyst.17. The method of claim 15 , wherein step 3 is not optional claim 15 , and Z′ is Calkyl-COOR claim 15 , and R is a Calkyl.18. The method of claim 15 , wherein step 3 is not optional claim 15 , and Rand Rare each CH claim 15 , Z is (CH)COO Rand Ris a cation or H.19. The method of claim 18 , wherein Ris a cation and the cation is K. This application claims priority from U.S. Provisional Application No. 61/497,754, filed Jun. 16, 2011, the entirety of which is incorporated herein by reference.The present application relates to a process for selectively producing single-isomer benzoprostacyclin derivatives including beraprost and its derivatives. The present invention also relates to a novel process for attaching the alpha side-chain to single-isomer key intermediate leading to beraprost and related derivatives.Prostacyclin derivatives are useful pharmaceutical ...

Подробнее
16-07-2015 дата публикации

Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof

Номер: US20150197486A9
Принадлежит: XenoPort Inc

Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

Подробнее
11-06-2020 дата публикации

COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS

Номер: US20200181057A1
Автор: Phares Ken
Принадлежит: United Therapeutics Corporation

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. 1. A pharmaceutical composition comprising a) treprostinil or a pharmaceutically acceptable salt or ester thereof and b) polysorbate 80.2. The pharmaceutical composition of in the form of a powder.3. The pharmaceutical composition of further comprising a buffer.4. The pharmaceutical composition of further comprising a buffer.5. The pharmaceutical composition of comprising a) a pharmaceutically acceptable salt of treprostinil and b) polysorbate 80.6. The pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable salt is treprostinil sodium.7. The pharmaceutical composition of in the form of a powder.8. The pharmaceutical composition of in the form of a powder.9. The pharmaceutical composition of further comprising a buffer.10. The pharmaceutical composition of further comprising a buffer.11. The pharmaceutical composition of further comprising a buffer.12. The pharmaceutical composition of further comprising a buffer. This application is a continuation of U.S. application Ser. No. 16/519,491, filed Jul. 23, 2019, which is a continuation of U.S. application Ser. No. 15/875,101, filed Jan. 19, 2018, which is a continuation of U.S. application Ser. No. 15/239,014, filed Aug. 17, 2016, which is a continuation of U.S. application Ser. No. 14/881,379, filed Oct. 13, 2015, which is a divisional of U.S. application Ser. No. 14/710,694, filed May 13, 2015, which is a continuation of U.S. application Ser. No. 14/490,014, filed Sep. 18, 2014, which is a Continuation of U.S. application Ser. No. 13/906,585, filed May 31, 2013, which is a divisional of U.S. application Ser. No. 13/558,757, filed Jul. 26, 2012, which is a ...

Подробнее
14-07-2016 дата публикации

Antibacterial Compounds

Номер: US20160200673A1
Принадлежит:

Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, Y, Z, X, R, R, R, R, Y, Z, X, and Xare defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as bacterial infections. 5. (canceled)7. A compound according to claim 6 , wherein Ris Chaloalkyl.8. A compound according to claim 7 , wherein Ris —CHF claim 7 , —CHF claim 7 , or —CF.9. A compound according to claim 8 , wherein Ris —CHF.1016-. (canceled)17. A compound according to claim 6 , wherein Ris methyl or hydrogen claim 6 , and Ris —CHF.1826-. (canceled)27. A compound according to claim 7 , wherein Ris —CONH—OH claim 7 , —CONH—NH claim 7 , or —COH.2858-. (canceled)6170-. (canceled)72. (canceled)73. (canceled)75109-. (canceled)110. A compound according to claim 60 , wherein Zis heteroaryl optionally substituted with R.111117-. (canceled)119. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier claim 1 , solvent claim 1 , adjuvant or diluent.120Neisseria gonorrhoeae. A method of treating Gram-negative or bacterial infections claim 1 , the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to .121127-. (canceled)128. A pharmaceutical composition comprising a compound according and a pharmaceutically acceptable carrier claim 60 , solvent claim 60 , adjuvant or diluent.130Neisseria gonorrhoeae. A method of treating Gram-negative or bacterial infections claim 60 , the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to . This application claims the benefit of U.S. Provisional Patent Application No. 61/866,845, filed Aug. 16, 2013, U.S. Provisional Patent Application No. 61/867,903, filed Aug. 20, 2013, and U.S. Provisional Patent Application No. 61/907,705, filed Nov. 22, 2013, each of which is ...

Подробнее